ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) | |
(Address of principal executive offices) |
(Zip Code) |
Title of Each Class |
Trading Symbol |
Name of Each Exchange on Which Registered | ||
☒ |
Accelerated filer |
☐ | ||||
Non-accelerated filer |
☐ |
Smaller reporting company |
||||
Emerging growth company |
PART I |
||||||
3 |
||||||
30 |
||||||
50 |
||||||
50 |
||||||
50 |
||||||
50 |
||||||
PART II |
||||||
51 |
||||||
54 |
||||||
56 |
||||||
74 |
||||||
75 |
||||||
109 |
||||||
109 |
||||||
109 |
||||||
PART III |
||||||
111 |
||||||
111 |
||||||
111 |
||||||
111 |
||||||
112 |
||||||
PART IV |
||||||
113 |
||||||
117 |
ITEM 1. |
BUSINESS |
• | Build upon core competencies . |
• | Promote same-unit and organic growth . |
• | Acquire physician practice groups. |
• | Strengthen and broaden relationships with our partners . |
• | Focus on transformation and restructuring initiatives |
external resources. We believe these strategic initiatives, together with our continued plans to invest in focused, targeted and strategic organic and acquisitive growth, position us well to deliver a differentiated value proposition to our stakeholders while continuing to provide the highest quality care for our patients. |
• | Clinical Research. in-depth look at our specialties. This nationwide perspective allows us to better anticipate future needs and opportunities. |
• | Quality and Safety. |
• | Continuous Quality Improvement (“CQI”) . |
• | Patient Safety Organization (“PSO”). |
and analysis of quality data. As a federally-listed PSO, our mission to improve the safety of care rendered is supported by the dissemination of best practices information and implementation of patient safety programs. Both our anesthesiology HRO program and Women’s and Children’s HRO program aim to provide “Just Culture” training to our clinicians. The complex curriculum has been customized to meet our affiliated physician practices’ needs and is based on principles outlined by the Agency for Healthcare Research and Quality (“AHRQ”), Institute for Healthcare Improvement, National Patient Safety Foundation and Team STEPPS, the teamwork system developed by the AHRQ and the Department of Defense. |
• | Simulation. in situ low-volume critical situations. To meet the needs of our health care providers, hospital and ASC partners, as well as our patients, MEDNAX offers a variety of customized simulation programs with the aim of instilling competence and confidence with one goal in mind: improved outcomes. Our Simulation Program has gained provisional accreditation by the Society for Simulation in Healthcare, a required first step towards attaining full accreditation, and currently offers highly interactive programs for neonatology, anesthesiology and hospital-based medicine practices. The effects of simulation are proven as a performance improvement method and are known to lead to enhanced communication and improved patient outcomes. |
• | Education. |
• | Innovation. point-of-care diagnostics and advanced data analytics are currently shaping the future of medicine. Our team is actively engaged in designing projects that we believe will allow us to prevent disease, offer precision care and further optimize patient outcomes. |
• | BabySteps ® . |
MEDNAX Clinical App (“MCA”). The NICU version will be referred to as “BabySteps 2.0,” but this advance provides an opportunity to expand use of the application to our other hospital-based specialties. MCA/BabySteps 2.0 is currently being piloted in certain locations with a plan to roll it out across additional NICUs in 2020. The plan for broader use across other hospital-based specialties is under development. |
• | Clinical Data Warehouse. de-identify and transfer data from our electronic health records that reside in BabySteps to our “clinical data warehouse” that since inception has accumulated clinical information on more than 1.5 million patients and over 27 million patient days. With comprehensive reporting tools, our physicians are able to use this information to benchmark outcomes, enhance clinical decision-making and advance best practices at the bedside. Using a variety of clinical performance markers, our de-identified data warehouse also helps us track medication and procedure interactions, link treatments to outcomes and identify opportunities to enhance patient outcomes. Our clinical data warehouse also helps us to identify which prospective clinical trials are most important and allows us to monitor the impact of our continuous quality improvement initiatives. |
• | MEDNAX Qualified Clinical Data Registry (“QCDR”) |
• | Nextgen ® . |
• | Charge Capture. |
• | Radiology Clinical Data Warehouse. |
• | MEDNAX Learning Center ® . web-based education platforms also function as important educational adjuncts to our affiliated physician groups, providing |
a rich source of ongoing medical education for our physicians and enabling physicians to discuss cases with one another through various clinical resources. |
• | Unit Management |
• | Staffing and Scheduling non-medical personnel for our affiliated physician groups. |
• | Recruiting and Credentialing |
• | Billing, Collection and Reimbursement |
physicians. We provide our affiliated physicians and other clinicians with a training curriculum that emphasizes detailed documentation of and compliant coding protocols for all procedures performed and services provided, and we provide comprehensive internal auditing processes, all of which are designed to achieve compliant coding, billing and collection of revenue for physician services. Generally, our billing and collection operations are conducted from our business offices located across the United States and in Puerto Rico, as well as our corporate offices. |
• | Risk Management |
• | Compliance |
• | Other Services |
• | a Chief Compliance Officer who reports to the Board of Directors on a regular basis; |
• | a Compliance Committee consisting of our senior executives; |
• | a formal internal audit function, including a Senior Director of Internal Audit who reports to the Audit Committee on a regular basis; |
• | our Code of Conduct |
• | our Code of Professional Conduct – Finance |
• | a disclosure program that includes a mechanism to enable individuals to disclose on a confidential or anonymous basis to the Chief Compliance Officer or any person who is not in the disclosing individual’s chain of command, issues or questions believed by the individual to be a potential violation of criminal, civil, or administrative laws or of company policies or procedures; |
• | an organizational structure designed to integrate our compliance objectives into our corporate offices, regions and practices; and |
• | education, monitoring and corrective action programs designed to establish methods to promote the understanding of our Compliance Program and adherence to its requirements. |
ITEM 1A. |
RISK FACTORS |
• | federal laws (including the federal FCA) that prohibit entities and individuals from intentionally (or with reckless disregard or deliberate ignorance) presenting or causing to be presented false or fraudulent claims to Medicare, Medicaid and other government-funded programs, or improperly retaining known overpayments; |
• | When an entity is determined to have violated the federal FCA, it must pay three times the actual damages sustained by the government, plus mandatory civil penalties of between $11,463 and $22,927 for each separate false claim. Suits filed under the federal FCA, known as “qui tam” actions, can be brought by any individual on behalf of the government and such individuals (known as “relators” or, more commonly, as “whistleblowers”) may share in any amounts paid by the entity to the government in fines or settlement. In addition, certain states have enacted laws modeled after the federal FCA. Qui tam actions have increased significantly in recent years, causing greater numbers of healthcare companies to have to defend a false claim action, even before the validity of the claim is established and even if the government decides not to intervene in the lawsuit. Healthcare entities may decide to agree to large settlements with the government and/or whistleblowers to avoid the cost and negative publicity associated with litigation. |
• | The ACA amended federal law to provide that the government may assert that a claim including items or services resulting from a violation of the federal anti-kickback statute constitutes a false or fraudulent claim for purposes of the federal civil FCA. Criminal prosecution is possible for knowingly making or presenting a false or fictitious or fraudulent claim to the federal government. |
• | a provision of the Social Security Act, commonly referred to as the federal “anti-kickback” statute, that prohibits the knowing and willful offer, payment, solicitation or receipt of any bribe, kickback, rebate or other remuneration, in cash or in kind, in return for the referral or recommendation of patients for, or for the purchasing, leasing, ordering or arranging for, items and services for which payment may be made, in whole or in part, by federal healthcare programs, such as Medicare and Medicaid; |
• | The definition of “remuneration” has been broadly interpreted to include anything of value, including such items as gifts, discounts, the furnishing of supplies or equipment, credit arrangements, waiver of payments, and providing anything at less than its fair market value. The HHS Office of the Inspector General has issued regulations, commonly known as safe harbors, that set forth certain provisions which, if satisfied in their entirety, will assure healthcare providers and other parties that they will not be prosecuted under the federal anti-kickback statute. The failure of a transaction or arrangement to fit precisely within one or more safe harbors does not necessarily mean that it is illegal or that prosecution will be pursued. However, conduct and business arrangements that do not fully satisfy each applicable safe harbor element may result in |
increased scrutiny by government enforcement authorities or invite litigation by private citizens under state or federal false claims statutes. |
• | Our relationships with referral sources, including GHC Program patients, are subject to scrutiny under the federal anti-kickback statute and must be structured in a manner to promote compliance. |
• | The penalties for violating the federal anti-kickback statute include imprisonment for up to ten years, fines of up to $100,000 per violation and possible exclusion from federal healthcare programs such as Medicare and Medicaid. Many states have adopted prohibitions similar to the federal Anti-Kickback Statute, some of which apply to the referral of patients for healthcare services reimbursed by any source, not only by the government programs such as Medicare and Medicaid. |
• | a provision of the Social Security Act, the federal Physician Self-Referral Law, commonly referred to as the Stark Law, that, subject to certain exceptions, prohibits physicians from making a referral to an entity for certain “designated health services” or “DHS” payable by Medicare if the physician, or an immediate family member of the physician, has a direct or indirect financial relationship (including ownership interests and compensation arrangements) with the entity. The Stark Law also prohibits such an entity from presenting or causing to be presented a claim to Medicare for DHS provided pursuant to a prohibited referral, and provides that certain collections related to any such claims must be refunded in a timely manner. Although the Stark Law is drafted to apply only to Medicare claims, the DOJ has taken the position that it applies to Medicaid claims under an extension of the federal FCA and several courts, including courts in Florida and Texas, have agreed. |
• | The Stark Law is a strict liability statute and therefore, any referrals for Medicare DHS pursuant to a financial relationship that does not meet an exception will be nonpayable and subject to refund to Medicare. In 2010, Congress instructed that any Medicare “overpayment” (that is, Medicare funds to which a person is not entitled) must be returned within 60 days of identification—or risk liability under the FCA’s “obligation” provision. Therefore, claims relating to Stark Law violations must be timely refunded to Medicare or we would risk liability under the federal FCA. |
• | All of our relationships with referring physicians will implicate the Stark Law, including our ownership, physician employment, independent contractor physicians, lease arrangements with physicians, nonmonetary compensation to physicians, and our relationships with hospitals and other entities. Each such financial relationship must satisfy a Stark Law exception. |
• | Because our practices provide DHS within the practice (e.g., radiology services, outpatient drugs, laboratory services, etc.), an exception to the Stark Law must be met with respect to those referrals. Generally, the In-Office Ancillary Services (“IOAS”) Exception is utilized for referrals of DHS made within a physician’s group practice. Alternatively, the Physician Services Exception could also be used to shield referrals of physician services within a physician group. In order to utilize both the IOAS Exception and the Physician Services Exception, the group must, among other things, satisfy the Stark Law’s definition of a “group practice.” The group practice definition also encompasses how a physician practice may compensate its physician shareholders, employees, and independent contractors. For example, group practices are not permitted to distribute profits derived from DHS based directly on the volume or value of referrals. However, there are a number of ways that a group practice can distribute profits, including DHS profits, to its physicians, based indirectly upon referrals, without running afoul of the Stark Law. Our ancillary services revenues must be allocated in a compliant manner to avoid falling outside of the Group Practice definition, which would result in all of our Medicare (and potentially, Medicaid) DHS referral revenues becoming nonpayable and subject to refund. |
• | Violations of the Stark Law result in civil penalties and program exclusions for knowing violations, civil assessment of up to three times the amount claimed. federal law such as the Civil Monetary Penalties Law (“CMPL”) that imposes substantial civil monetary penalties against an entity that |
engages in prohibited activities including but not limited to violations of the Stark or Anti-Kickback laws, knowing submission of a false or fraudulent claim, employment of an excluded individual and the provision or offer of anything of value to a Medicare or Medicaid beneficiary that the transferring party knows or should know is likely to influence beneficiary selection of a particular provider for which payment may be made in whole or in part by Medicare or Medicaid; |
• | “Remuneration” is defined under the CMPL as any transfer of items or services for free or for less than fair market value. There are certain exceptions to the definition of remuneration for offerings that meet the Financial Need, Preventative Care, or Promoting Access to Care exceptions. Sanctions for violations of the CMPL include civil monetary penalties and administrative penalties up to and including exclusion from participation in federal health care programs. |
• | similar state law provisions pertaining to anti-kickback, fee splitting, self-referral and false claims, and other fraud and abuse issues which typically are not limited to relationships involving government-funded programs. In some cases these laws prohibit or regulate additional conduct beyond what federal law affects, including applicability to items and services paid by commercial insurers and private pay patients. Penalties for violating these laws can range from fines to criminal sanctions; |
• | provisions of 18 U.S.C. § 1347 that prohibit knowingly and willfully executing a scheme or artifice to defraud a healthcare benefit program or falsifying, concealing or covering up a material fact or making any material false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services; |
• | federal and state laws related to confidentiality, privacy and security of personal information such as HIPAA, including medical information and records, that limit the manner in which we may use and disclose that information, impose obligations to safeguard that information and require that we notify third parties in the event of a breach; |
• | HIPAA violations can result in both civil monetary penalties and criminal sanctions. HIPAA has ranges of increasing minimum penalty amounts tiered according to the entity’s degree of culpability, with a maximum penalty of $1,500,000 for all violations of an identical provision within a year. Further, HHS has obtained increasingly high dollar settlements from covered entities relating to HIPAA violations over the past several years. |
• | Unsecured Breaches of PHI may also result in unexpected costs in the millions of dollars to us through third party litigation, contractual breaches, and breach notification and remediation. In addition, we may experience reputational harms and a negative market perception when it comes to protecting patient data that could influence our future operations. |
• | state laws that prohibit general business corporations from practicing medicine, controlling physicians’ medical decisions or engaging in certain practices, such as splitting fees with physicians; |
• | federal and state laws governing participation in GHC Programs could result in denial of our application to become a participating provider or revocation of our participation or billing privileges, which in turn, could cause us to not be able to treat patients covered by the applicable program or prohibit us from billing for the treatment services provided to such patients; |
• | federal and state laws that prohibit providers from billing and receiving payment from Medicare and Medicaid for services unless the services are medically necessary, adequately and accurately documented and billed using codes that accurately reflect the services rendered; |
• | federal and state laws pertaining to the provision and coverage of services by non-physician practitioners, such as advanced nurse practitioners, physician assistants and other clinical professionals, physician supervision of such services and reimbursement requirements that may be dependent on the manner in which the services are provided and documented; and |
• | federal laws that impose civil administrative sanctions for, among other violations, inappropriate billing of services to federal healthcare programs, inappropriately reducing hospital inpatient lengths of |
stay for such patients, or employing individuals who are excluded from participation in federally funded healthcare programs. |
• | Provisions of HIPAA that limit how covered entities and business associates may use and disclose PHI, provide certain rights to individuals with respect to that information and impose certain security requirements; |
• | HITECH, which required the OCR to strengthen and expand the HIPAA Privacy Rule and Security Rule and imposes data breach notification obligations; |
• | Other federal and state laws restricting the use and protecting the privacy and security of personal information, including health information, many of which are not preempted by HIPAA, and certain states have proposed or enacted legislation that will create new data privacy and security obligations for certain entities, such as the California Consumer Protection Act (CCPA); |
• | Federal and state consumer protection laws; and |
• | Federal and state laws regulating the conduct of research with human subjects. |
• | We may not be able to identify suitable acquisition candidates or strategic opportunities or implement successfully or realize the expected benefits of any suitable opportunities. In addition, we compete for acquisitions with other potential acquirers, some of which may have greater financial or operational resources than we do. This competition may intensify due to the ongoing consolidation in the healthcare industry, which may increase our acquisition costs. |
• | We may not be able to complete acquisitions of physician practices or services companies or we may complete acquisitions on less favorable terms as a result of changes in tax laws, financial market or other economic or market conditions. |
• | We may not be able to successfully integrate completed acquisitions, including our recent acquisitions. Integrating completed acquisitions into our existing operations involves numerous short-term and long-term risks, including diversion of our management’s attention, failure to retain key personnel, long-term value of acquired intangible assets and acquisition expenses. In addition, we may be required to comply with laws, rules and regulations that may differ not only from those of the states in which our operations are currently conducted but from an expansion in the service offerings we provide in certain states for which the laws, rules and regulations may be different. |
• | We cannot be certain that any acquired business will continue to maintain its pre-acquisition revenue and growth rates or be financially successful. In addition, we cannot be certain of the extent of any unknown or contingent liabilities of any acquired business, including liabilities for failure to comply with applicable laws, or liabilities relating to medical malpractice claims. Generally, we obtain indemnification agreements from the sellers of businesses acquired with respect to pre-closing acts, omissions and other similar risks. It is possible that we may seek to enforce indemnification provisions in the future against sellers who may no longer have the financial wherewithal to satisfy their obligations to us. Accordingly, we may incur material liabilities for past activities of acquired businesses. |
• | We could incur or assume indebtedness and issue equity in connection with acquisitions. The issuance of shares of our common stock for an acquisition may result in dilution to our existing shareholders and, depending on the number of shares that we issue, the resale of such shares could affect the trading price of our common stock. |
• | We may acquire businesses that derive a greater portion of their revenue from GHC Programs than what we recognize on a consolidated basis or that have business models with lower operating margins than ours. These acquisitions could affect our overall payor mix or operating results in future periods. |
• | Acquisitions of practices and services companies could entail financial and operating risks not fully anticipated. Such acquisitions could divert management’s attention and our resources. |
• | An acquisition could be subject to a challenge under the antitrust laws either before or after it is consummated. Such a challenge could involve substantial legal costs and divert management’s attention and resources and could result in us having to abandon the transaction or make a divestiture. |
• | We may not be able to expand the services that our affiliated physicians provide to our hospital partners or the services provided by our services companies to their customers. |
• | We may not be able to attract referrals to our office-based practices or neonatology transports to our hospital-based units. |
• | We may not be able to execute new contractual arrangements with hospitals, including through joint ventures, where we either currently provide or do not currently provide physician services. |
• | We may not be able to work with our hospital partners to develop integrated services programs for which we become a multi-specialty provider of solutions within the maternal-fetal, newborn, pediatric continuum of care. |
• | We may not accurately project same-unit and organic growth performance, or we may experience a shift in the mix of services that certain of our customers request from us, potentially resulting in lower margins. |
• | a substantial portion of our cash flow from operations will be required to service interest and principal payments on our debt and will not be available for operations, working capital, capital expenditures, expansion, acquisitions, dividends or general corporate or other purposes; |
• | our ability to obtain additional financing in the future may be impaired; |
• | we may be more highly leveraged than our competitors, which may place us at a competitive disadvantage; |
• | our flexibility in planning for, or reacting to, changes in our business and industry may be limited; and |
• | we may be more vulnerable in the event of a downturn in our business, our industry or the economy in general. |
ITEM 1B. |
UNRESOLVED STAFF COMMENTS |
ITEM 2. |
PROPERTIES |
ITEM 3. |
LEGAL PROCEEDINGS |
ITEM 4. |
MINE SAFETY DISCLOSURES |
ITEM 5. |
MARKET FOR REGISTRANT’S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES |
|
Base Period |
Years Ended December 31, |
||||||||||||||||||||||
Company/Index |
2014 |
2015 |
2016 |
2017 |
2018 |
2019 |
||||||||||||||||||
MEDNAX, Inc. |
$ | 100.00 |
$ | 108.40 |
$ | 100.83 |
$ | 80.83 |
$ | 49.92 |
$ | 42.04 |
||||||||||||
S&P 500 Index |
$ | 100.00 |
$ | 99.27 |
$ | 108.74 |
$ | 129.86 |
$ | 121.76 |
$ | 156.92 |
||||||||||||
S&P 600 Health Care |
$ | 100.00 |
$ | 120.39 |
$ | 122.73 |
$ | 165.05 |
$ | 181.17 |
$ | 217.65 |
||||||||||||
NYSE Composite Index |
$ | 100.00 |
$ | 93.58 |
$ | 102.01 |
$ | 118.17 |
$ | 104.94 |
$ | 128.36 |
Period |
Total Number of Shares Repurchased (a) |
Average Price Paid per Share |
Total Number of Shares Purchased as part of the Repurchase Programs |
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Repurchase Programs (a) |
||||||||||||
October 1 – October 31, 2019 |
— |
$ | — |
— |
|
(a) | ||||||||||
November 1 – November 30, 2019 |
— |
— |
— |
|
(a) | |||||||||||
December 1 – December 31, 2019 |
13,577 |
$ | 26.12 |
(b) | — |
|
(a) | |||||||||
Total |
13,577 |
$ | 26.12 |
— |
|
(a) |
(a) | We have two active repurchase programs. Our July 2013 program allows us to repurchase shares of our common stock up to an amount sufficient to offset the dilutive impact from the issuance of shares under our equity compensation programs, which was estimated to be approximately 1.3 million shares for 2019, although no shares were repurchased under that program in 2019. Our August 2018 program allows us to repurchase up to an additional $500.0 million of shares of our common stock, of which we repurchased $392.8 million, leaving $107.2 million available as of December 31, 2019. |
(b) | Represents shares withheld to satisfy minimum statutory withholding obligations of $0.4 million in connection with the vesting of restricted stock. |
ITEM 6. |
SELECTED FINANCIAL DATA |
(in thousands, except per share and other operating data) |
2019 |
2018 |
2017 |
2016 |
2015 |
|||||||||||||||
Consolidated Income Statement Data: |
||||||||||||||||||||
Net revenue |
$ | 3,513,542 |
$ | 3,454,810 |
$ | 3,253,391 |
$ | 3,183,159 |
$ | 2,779,996 |
||||||||||
Operating expenses: |
||||||||||||||||||||
Practice salaries and benefits |
2,508,778 |
2,426,376 |
2,227,335 |
2,031,220 |
1,753,505 |
|||||||||||||||
Practice supplies and other operating expenses |
112,766 |
108,851 |
106,444 |
118,416 |
98,480 |
|||||||||||||||
General and administrative expenses |
404,643 |
403,934 |
385,864 |
372,572 |
305,915 |
|||||||||||||||
Depreciation and amortization |
78,860 |
83,832 |
78,856 |
89,264 |
64,228 |
|||||||||||||||
Transformational and restructuring related expenses |
95,329 |
— |
— |
— |
— |
|||||||||||||||
Goodwill impairment |
1,449,215 |
— |
— |
— |
— |
|||||||||||||||
Total operating expenses |
4,649,591 |
3,022,993 |
2,798,499 |
2,611,472 |
2,222,128 |
|||||||||||||||
(Loss) income from operations |
(1,136,049 |
) | 431,817 |
454,892 |
571,687 |
557,868 |
||||||||||||||
Investment and other income |
5,671 |
5,211 |
4,385 |
2,019 |
1,844 |
|||||||||||||||
Interest expense |
(119,381 |
) | (88,789 |
) | (74,556 |
) | (63,092 |
) | (23,110 |
) | ||||||||||
Equity in earnings of unconsolidated affiliates |
7,779 |
6,825 |
952 |
3,185 |
3,127 |
|||||||||||||||
Total non-operating expenses |
(105,931 |
) | (76,753 |
) | (69,219 |
) | (57,888 |
) | (18,139 |
) | ||||||||||
(Loss) income from continuing operations before income taxes |
(1,241,980 |
) | 355,064 |
385,673 |
513,799 |
539,729 |
||||||||||||||
Income tax benefit (provision) |
91,886 |
(96,453 |
) | (80,231 |
) | (189,203 |
) | (204,038 |
) | |||||||||||
(Loss) income from continuing operations |
(1,150,094 |
) | 258,611 |
305,442 |
324,596 |
335,691 |
||||||||||||||
(Loss) income from discontinued operations, net of tax |
(347,608 |
) | 10,018 |
14,930 |
318 |
629 |
||||||||||||||
Net (loss) income |
$ | (1,497,702 |
) | $ | 268,629 |
$ | 320,372 |
$ | 324,914 |
$ | 336,320 |
|||||||||
Per Common and Common Equivalent Share Data: |
||||||||||||||||||||
(Loss) income from continuing operations: |
||||||||||||||||||||
Basic |
$ | (13.78 |
) | $ | 2.84 |
$ | 3.31 |
— |
— |
|||||||||||
Diluted |
$ | (13.78 |
) | $ | 2.82 |
$ | 3.29 |
— |
— |
|||||||||||
(in thousands, except per share and other operating data) |
2019 |
2018 |
2017 |
2016 |
2015 |
|||||||||||||||
(Loss) income from discontinued operations: |
||||||||||||||||||||
Basic |
$ | (4.16 |
) | $ | 0.11 |
$ | 0.16 |
— |
— |
|||||||||||
Diluted |
$ | (4.16 |
) | $ | 0.11 |
$ | 0.16 |
— |
— |
|||||||||||
Net (loss) income: |
||||||||||||||||||||
Basic |
$ | (17.94 |
) | $ | 2.95 |
$ | 3.47 |
$ | 3.52 |
$ | 3.61 |
|||||||||
Diluted |
$ | (17.94 |
) | $ | 2.93 |
$ | 3.45 |
$ | 3.49 |
$ | 3.58 |
|||||||||
Weighted average common shares: |
||||||||||||||||||||
Basic |
83,495 |
91,104 |
92,431 |
92,422 |
93,077 |
|||||||||||||||
Diluted |
83,495 |
91,606 |
92,958 |
93,109 |
93,960 |
|||||||||||||||
Other Operating Data: |
||||||||||||||||||||
Number of physicians at end of year |
4,327 |
4,214 |
4,083 |
3,617 |
3,240 |
|||||||||||||||
Number of births |
792,040 |
793,918 |
808,465 |
807,285 |
803,311 |
|||||||||||||||
NICU admissions |
114,864 |
113,485 |
112,965 |
112,184 |
111,407 |
|||||||||||||||
NICU patient days |
2,014,166 |
1,977,516 |
1,990,521 |
1,977,204 |
1,960,768 |
|||||||||||||||
Number of anesthesia cases |
1,793,349 |
1,844,451 |
1,924,952 |
1,827,194 |
1,533,089 |
|||||||||||||||
Number of radiology studies (1) |
12,028,009 |
11,505,524 |
10,166,227 |
5,755,853 |
5,317,309 |
|||||||||||||||
Consolidated Balance Sheet Data (Continuing Operations): |
||||||||||||||||||||
Cash and cash equivalents |
$ | 112,767 |
$ | 25,491 |
$ | 46,357 |
$ | 55,698 |
$ | 51,572 |
||||||||||
Working capital |
189,689 |
129,008 |
55,565 |
138,179 |
98,998 |
|||||||||||||||
Total assets |
4,145,901 |
5,246,297 |
5,160,065 |
5,339,400 |
4,547,214 |
|||||||||||||||
Total liabilities |
2,646,905 |
2,790,168 |
2,747,133 |
2,578,633 |
2,109,368 |
|||||||||||||||
Borrowings under credit facility |
— |
739,500 |
1,110,500 |
963,500 |
533,500 |
|||||||||||||||
Senior notes outstanding |
1,750,000 |
1,250,000 |
750,000 |
750,000 |
750,000 |
|||||||||||||||
Total equity |
1,498,996 |
2,456,129 |
2,412,932 |
2,760,767 |
2,437,846 |
(1) |
Represents estimated annualized number of studies for years in which acquisitions took place. Does not include studies for the radiology practice acquisition that took place on December 31, 2019. |
ITEM 7. |
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
Years Ended December 31, |
||||||||||||
2019 |
2018 |
2017 |
||||||||||
Contracted managed care |
69 |
% | 70 |
% | 70 |
% | ||||||
Government |
24 |
% | 24 |
% | 25 |
% | ||||||
Other third-parties |
5 |
% | 4 |
% | 4 |
% | ||||||
Private-pay patients |
2 |
% | 2 |
% | 1 |
% | ||||||
100 |
% | 100 |
% | 100 |
% | |||||||
• | There are fewer calendar days in the first and second quarters of the year, as compared to the third and fourth quarters of the year. Because we provide services in NICUs on a 24-hours-a-day basis, 365 days a year, any reduction in service days will have a corresponding reduction in net revenue. |
• | The majority of physician services provided by our office-based and anesthesia practices consist of office visits and scheduled procedures that occur during business hours. As a result, volumes at those practices fluctuate based on the number of business days in each calendar quarter. |
• | A significant number of our employees and our associated professional contractors, primarily physicians, exceed the level of taxable wages for social security during the first and second quarters of the year. As a result, we incur a significantly higher payroll tax burden and our net income is lower during those quarters. |
Years Ended December 31, |
||||||||||||
2019 |
2018 |
2017 |
||||||||||
(Loss) income from continuing operations |
$ | (1,150,094 |
) | $ | 258,611 |
$ | 305,442 |
|||||
Interest expense |
119,381 |
88,789 |
74,556 |
|||||||||
Income tax (benefit) provision |
(91,886 |
) | 96,453 |
80,231 |
||||||||
Depreciation and amortization |
78,860 |
83,832 |
78,856 |
|||||||||
Transformational and restructuring related expenses |
95,329 |
— |
— |
|||||||||
Goodwill impairment |
1,449,215 |
— |
— |
|||||||||
Adjusted EBITDA from continuing operations |
$ | 500,805 |
$ | 527,685 |
$ | 539,085 |
||||||
Years Ended December 31, |
||||||||||||||||||||||||
2019 |
2018 |
2017 |
||||||||||||||||||||||
Weighted average diluted shares outstanding |
83,495 |
91,606 |
92,958 |
|||||||||||||||||||||
(Loss) income from continuing operations and diluted income from continuing operations per share |
$ | (1,150,094 |
) | $ | (13.78 |
) | $ | 258,611 |
$ | 2.82 |
$ | 305,442 |
$ | 3.29 |
||||||||||
Adjustments (1) : |
||||||||||||||||||||||||
Amortization (net of tax of $13,192, $14,793 and $20,452) |
35,668 |
0.43 |
39,743 |
0.43 |
32,042 |
0.34 |
||||||||||||||||||
Stock-based compensation (net of tax of $9,544, $10,284 and $11,223) |
25,807 |
0.31 |
27,626 |
0.30 |
17,555 |
0.19 |
||||||||||||||||||
Transformational and restructuring related expenses (net of tax of $25,739) |
69,590 |
0.83 |
— |
— |
— |
— |
||||||||||||||||||
Goodwill impairment (net of tax of $147,215) |
1,302,000 |
15.59 |
— |
— |
— |
— |
||||||||||||||||||
Net impact from discrete tax events |
(773 |
) | — |
— |
— |
(70,014 |
) | (0.75 |
) | |||||||||||||||
Adjusted income and diluted EPS from continuing operations |
$ | 282,198 |
$ | 3.38 |
$ | 325,980 |
$ | 3.55 |
$ | 285,025 |
$ | 3.07 |
||||||||||||
(1) | Tax rates of 27.0%, 27.1% and 39.0% were used to calculate the tax effects of the adjustments for the year ended December 31, 2019, 2018 and 2017, respectively. The tax rates used for the years ended December 31, 2019 and 2017 exclude the impact of discrete tax events. |
Years Ended December 31, |
||||||||||||
2019 |
2018 |
2017 |
||||||||||
Net revenue |
100.0 |
% | 100.0 |
% | 100.0 |
% | ||||||
Operating expenses: |
||||||||||||
Practice salaries and benefits |
71.4 |
70.2 |
68.5 |
|||||||||
Practice supplies and other operating expenses |
3.2 |
3.2 |
3.2 |
|||||||||
General and administrative expenses |
11.5 |
11.7 |
11.9 |
|||||||||
Depreciation and amortization |
2.2 |
2.4 |
2.4 |
|||||||||
Transformational and restructuring related expenses |
2.7 |
— |
— |
|||||||||
Goodwill impairment |
41.3 |
— |
— |
|||||||||
Total operating expenses |
132.3 |
87.5 |
86.0 |
|||||||||
(Loss) income from operations |
(32.3 |
) | 12.5 |
14.0 |
||||||||
Non-operating expense, net |
3.0 |
2.2 |
2.1 |
|||||||||
(Loss) income from continuing operations before income taxes |
(35.3 |
) | 10.3 |
11.9 |
||||||||
Income tax benefit (provision) |
2.6 |
(2.8 |
) | (2.5 |
) | |||||||
(Loss) income from continuing operations |
(32.7 |
)% | 7.5 |
% | 9.4 |
% |
Years Ended December 31, |
||||||||||||
2019 |
2018 |
2017 |
||||||||||
Operating activities |
$ | 338,467 |
$ | 274,108 |
$ | 483,367 |
||||||
Investing activities |
121,878 |
(124,380 |
) | (552,990 |
) | |||||||
Financing activities |
(393,070 |
) | (170,594 |
) | 90,345 |
Payments Due |
||||||||||||||||||||
Obligation |
Total |
2020 |
2021 and 2022 |
2023 and 2024 |
2025 and Later |
|||||||||||||||
Senior notes (1) |
$ | 2,344,116 |
$ | 101,875 |
$ | 203,750 |
$ | 911,094 |
$ | 1,127,397 |
||||||||||
Operating leases |
102,184 |
25,060 |
41,703 |
22,214 |
13,207 |
|||||||||||||||
$ | 2,446,300 |
$ | 126,935 |
$ | 245,453 |
$ | 933,308 |
$ | 1,140,604 |
|||||||||||
(1) |
Amounts include interest payments at the applicable rate as of December 31, 2019 and assume the amount outstanding under our 2023 Notes and the 2027 Notes will be paid on their maturity dates of December 1, 2023 and January 15, 2027, respectively. |
ITEM 7A. |
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
ITEM 8. |
FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA |
Page |
||||
Consolidated Financial Statements |
||||
76 |
||||
80 |
||||
81 |
||||
82 |
||||
83 |
||||
84 |
||||
Financial Statement Schedule |
||||
113 |
/s/ PricewaterhouseCoopers LLP |
Miami, Florida |
February 20, 2020 |
December 31, |
||||||||
2019 |
2018 |
|||||||
ASSETS |
||||||||
Current assets: |
||||||||
Cash and cash equivalents |
$ | |
$ | |
||||
Restricted cash |
|
|
||||||
Short-term investments |
|
|
||||||
Accounts receivable, net |
|
|
||||||
Prepaid expenses |
|
|
||||||
Other current assets |
|
|
||||||
Assets held for sale |
|
|
||||||
Total current assets |
|
|
||||||
Investments |
|
|
||||||
Property and equipment, net |
|
|
||||||
Goodwill |
|
|
||||||
Intangible assets, net |
|
|
||||||
Operating lease right-of-use assets |
|
|
||||||
Deferred income tax assets |
|
|
||||||
Other assets |
|
|
||||||
Assets held for sale |
|
|
||||||
Total assets |
$ | |
$ | |
||||
LIABILITIES & SHAREHOLDERS’ EQUITY |
||||||||
Current liabilities: |
||||||||
Accounts payable and accrued expenses |
$ | |
$ | |
||||
Current portion of finance lease liabilities |
|
|
||||||
Current portion of operating lease liabilities |
|
|
||||||
Income taxes payable |
|
|
||||||
Liabilities held for sale |
|
|
||||||
Total current liabilities |
|
|
||||||
Line of credit |
|
|
||||||
Long-term debt and finance lease liabilities, net |
|
|
||||||
Long-term operating lease liabilities |
|
|
||||||
Long-term professional liabilities |
|
|
||||||
Deferred income tax liabilities |
|
|
||||||
Other liabilities |
|
|
||||||
Liabilities held for sale |
|
|
||||||
Total liabilities |
|
|
||||||
Commitments and contingencies |
|
|
|
|
|
|
|
|
Shareholders’ equity: |
||||||||
Preferred stock; $ par value; |
|
|
||||||
Common stock; $ par value; |
|
|
||||||
Additional paid-in capital |
|
|
||||||
Retained earnings |
|
|
||||||
Total shareholders’ equity |
|
|
||||||
Total liabilities and shareholders’ equity |
$ | |
$ | |
||||
Years Ended December 31, |
||||||||||||
2019 |
2018 |
2017 |
||||||||||
Net revenue |
$ |
|
$ |
|
$ |
|
||||||
Operating expenses: |
||||||||||||
Practice salaries and benefits |
|
|
|
|||||||||
Practice supplies and other operating expenses |
|
|
|
|||||||||
General and administrative expenses |
|
|
|
|||||||||
Depreciation and amortization |
|
|
|
|||||||||
Transformational and restructuring related expenses |
|
|
|
|
|
|
|
|
|
| ||
Goodwill impairment |
|
|
|
|||||||||
Total operating expenses |
|
|
|
|||||||||
(Loss) income from operations |
( |
) |
|
|
||||||||
Investment and other income |
|
|
|
|||||||||
Interest expense |
( |
) |
( |
) |
( |
) | ||||||
Equity in earnings of unconsolidated affiliates |
|
|
|
|||||||||
Total non-operating expenses |
( |
) |
( |
) |
( |
) | ||||||
(Loss) income from continuing operations before income taxes |
( |
) |
|
|
||||||||
Income tax benefit (provision) |
|
( |
) |
( |
) | |||||||
(Loss) income from continuing operations |
( |
) |
|
|
||||||||
(Loss) income from discontinued operations, net of tax |
( |
) |
|
|
||||||||
Net (loss) income |
$ |
( |
) |
$ |
|
$ |
|
|||||
Per common and common equivalent share data: |
||||||||||||
(Loss) income from continuing operations: |
|
|
|
|
|
|
|
|
| |||
Basic |
|
$ |
( |
) |
|
$ |
|
|
|
$ |
|
|
Diluted |
|
$ |
( |
) |
|
$ |
|
|
|
$ |
|
|
(Loss) income from discontinued operations: |
|
|
|
|
|
|
|
|
| |||
Basic |
|
$ |
( |
) |
|
$ |
|
|
|
$ |
|
|
Diluted |
|
$ |
( |
) |
|
$ |
|
|
|
$ |
|
|
Net (loss) income: |
|
|
|
|
|
|
|
|
| |||
Basic |
|
$ |
( |
) |
|
$ |
|
|
|
$ |
|
|
Diluted |
|
$ |
( |
) |
|
$ |
|
|
|
$ |
|
|
Weighted average common shares: |
|
|
|
|
|
|
|
|
| |||
Basic |
|
|
|
|
|
|
|
|
|
|
|
|
Diluted |
|
|
|
|
|
|
|
|
|
|
|
|
|
Common Stock |
|
|
|
||||||||||||||||
|
Number of Shares |
|
Additional Paid-in Capital |
Retained Earnings |
Total Equity |
|||||||||||||||
|
Amount |
|||||||||||||||||||
Balance at December 31, 2016 |
|
$ | |
$ | |
$ | |
$ | |
|||||||||||
Net income |
— |
— |
— |
|
|
|||||||||||||||
Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan |
|
|
|
— |
|
|||||||||||||||
Issuance of restricted stock |
|
|
( |
) | — |
— |
||||||||||||||
Issuance of restricted stock for acquisition consideration |
|
|
|
— |
|
|||||||||||||||
Stock-based compensation expense |
— |
— |
|
— |
|
|||||||||||||||
Forfeitures of restricted stock |
( |
) | ( |
) | |
— |
— |
|||||||||||||
Repurchased common stock |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||
Balance at December 31, 2017 |
|
$ | |
$ | |
$ | |
$ | |
|||||||||||
Net income |
— |
— |
— |
|
|
|||||||||||||||
Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan |
|
|
|
— |
|
|||||||||||||||
Issuance of restricted stock |
|
|
( |
) | — |
— |
||||||||||||||
Stock-based compensation expense |
— |
— |
|
— |
|
|||||||||||||||
Stock swaps |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||||||
Forfeitures of restricted stock |
( |
) | ( |
) | |
— |
— |
|||||||||||||
Repurchased common stock |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||
Balance at December 31, 2018 |
|
$ | |
$ | |
$ | |
$ | |
|||||||||||
Net loss |
— |
— |
— |
( |
) | ( |
) | |||||||||||||
Unrealized holding gain on investments, net of tax(1) |
|
|
||||||||||||||||||
Common stock issued under employee stock option, employee stock purchase plan and stock purchase plan |
|
|
|
— |
|
|||||||||||||||
Issuance of restricted stock |
|
|
( |
) | — |
— |
||||||||||||||
Stock-based compensation expense |
— |
— |
|
— |
|
|||||||||||||||
Stock swaps |
( |
) | |
( |
) | ( |
) | |||||||||||||
Forfeitures of restricted stock |
( |
) | ( |
) | |
— |
— |
|||||||||||||
Repurchased common stock |
( |
) | ( |
) | ( |
) | ( |
) | ( |
) | ||||||||||
Balance at December 31, 2019 |
|
$ | |
$ | |
$ | |
$ | |
|||||||||||
(1) |
Presented within retained earnings on both the Consolidated Balance Sheets and the Consolidated Statements of Equity as the balance is immaterial. |
Years Ended December 31, |
||||||||||||
2019 |
||||||||||||
Cash flows from operating activities: |
||||||||||||
Net (loss) income |
$ |
( |
) |
$ |
$ |
|||||||
Loss (income) from discontinued operations |
( |
) |
( |
) | ||||||||
Adjustments to reconcile net income to net cash provided from operating activities: |
||||||||||||
Depreciation and amortization |
||||||||||||
Goodwill impairment |
||||||||||||
Amortization of premiums, discounts and issuance costs |
||||||||||||
Stock-based compensation expense |
||||||||||||
Deferred income taxes |
( |
) |
( |
) |
( |
) | ||||||
Other |
( |
) |
( |
) | ||||||||
Changes in assets and liabilities: |
||||||||||||
Accounts receivable |
( |
) |
||||||||||
Prepaid expenses and other current assets |
( |
) |
( |
) |
( |
) | ||||||
Other long-term assets |
( |
) | ||||||||||
Accounts payable and accrued expenses |
||||||||||||
Income taxes payable |
( |
) |
( |
) |
||||||||
Payments of contingent consideration liabilities |
( |
) |
( |
) |
( |
) | ||||||
Long-term professional liabilities |
( |
) |
||||||||||
Other liabilities |
( |
) |
( |
) |
( |
) | ||||||
Net cash provided by operating activities – continuing operations |
||||||||||||
Net cash provided by operating activities – discontinued operations |
||||||||||||
Net cash provided by operating activities |
||||||||||||
Cash flows from investing activities: |
||||||||||||
Acquisition payments, net of cash acquired |
( |
) |
( |
) |
( |
) | ||||||
Purchases of investments |
( |
) |
( |
) |
( |
) | ||||||
Proceeds from maturities or sales of investments |
||||||||||||
Purchases of property and equipment |
( |
) |
( |
) |
( |
) | ||||||
Proceeds from sales of businesses |
||||||||||||
Other |
||||||||||||
Net cash provided by (used in) investing activities – continuing operations |
( |
) |
( |
) | ||||||||
Net cash used in investing activities – discontinued operations |
( |
) |
( |
) |
( |
) | ||||||
Net cash provided by (used in) investing activities |
( |
) |
( |
) | ||||||||
Cash flows from financing activities: |
||||||||||||
Borrowings on credit agreement |
||||||||||||
Payments on credit agreement |
( |
) |
( |
) |
( |
) | ||||||
Proceeds from issuance of senior notes |
||||||||||||
Payments for financing costs |
( |
) |
( |
) |
( |
) | ||||||
Payments of contingent consideration liabilities |
( |
) |
( |
) |
( |
) | ||||||
Payments on finance lease obligations |
( |
) |
( |
) |
( |
) | ||||||
Proceeds from issuance of common stock |
||||||||||||
Contribution from noncontrolling interests |
||||||||||||
Repurchases of common stock |
( |
) |
( |
) |
( |
) | ||||||
Net cash (used in) provided by financing activities – continuing operations |
( |
) |
( |
) |
||||||||
Net cash used in financing activities – discontinued operations |
( |
) |
( |
) | ||||||||
Net cash (used in) provided by financing activities |
( |
) |
( |
) |
||||||||
Net increase (decrease) in cash and cash equivalents |
( |
) |
||||||||||
Cash, cash equivalents and restricted cash at beginning of year |
||||||||||||
Less cash and cash equivalents of discontinued operations at end of year |
( |
) |
( |
) | ||||||||
Cash and cash equivalents and restricted cash at end of year |
$ |
$ |
$ |
|||||||||
Supplemental disclosure of cash flow information: |
||||||||||||
Cash paid for: |
||||||||||||
Interest |
$ |
$ |
$ |
|||||||||
Income taxes |
$ |
$ |
$ |
|||||||||
Non-cash investing and financing activities: |
||||||||||||
Value of common stock issued for acquisitions |
$ |
$ |
$ |
|||||||||
Equipment financed through finance leases |
$ |
$ |
$ |
|||||||||
Property and equipment included in accounts payabl e |
$ |
$ |
$ |
1. |
General: |
2. |
Summary of Significant Accounting Policies: |
Years Ended December 31, |
||||||||||||
2019 |
2018 |
2017 |
||||||||||
Women’s and Children’s services |
% | % | % | |||||||||
Anesthesiology and related |
% | % | % | |||||||||
Radiology |
% | % | % | |||||||||
% | % | % | ||||||||||
Fair Value |
||||||||||||
Fair Value Category |
December 31, 2019 |
December 31, 2018 |
||||||||||
Assets: |
||||||||||||
Money market funds |
Level 1 |
$ | $ | |||||||||
Short-term investments |
Level 2 |
(1) | ||||||||||
Company-owned life insurance |
Level 2 |
|||||||||||
Mutual funds |
Level 1 |
|||||||||||
Liabilities: |
||||||||||||
Contingent consideration |
Level 3 |
(1) |
Investments were measured at carrying value as of December 31, 2018. See table below. |
December 31, 2019 |
December 31, 2018 |
|||||||||||||||
Carrying Amount |
Fair Value |
Carrying Amount |
Fair Value |
|||||||||||||
Assets: |
||||||||||||||||
Short-term investments |
$ | (2) |
$ | (2) |
||||||||||||
Long-term investments |
(2) |
(2) |
||||||||||||||
Liabilities: |
||||||||||||||||
2023 Notes |
||||||||||||||||
2027 Notes |
(2) |
Investments were measured at fair value as of December 31, 2019. See table above. |
3. |
Investments: |
December 31, 2019 |
December 31, 2018 |
|||||||||||||||
Short- Term |
Long-Term |
Short-Term |
Long-Term |
|||||||||||||
Corporate securities |
$ | $ | $ | $ | ||||||||||||
Municipal debt securities |
||||||||||||||||
Federal home loan securities |
||||||||||||||||
Certificates of deposit |
||||||||||||||||
$ | $ | $ | $ | |||||||||||||
4. |
Accounts Receivable and Net Revenue: |
December 31, |
||||||||
2019 |
2018 |
|||||||
Gross accounts receivable |
$ | $ | ||||||
Allowance for contractual adjustments and uncollectibles |
( |
) | ( |
) | ||||
$ | $ | |||||||
Years Ended December 31, |
||||||||||||
2019 |
2018 |
2017 |
||||||||||
Net patient service revenue |
$ | $ | $ | |||||||||
Hospital contract administrative fees |
||||||||||||
Other revenue |
||||||||||||
$ | 3,513,542 |
$ | $ | |||||||||
Years Ended December 31, |
||||||||||||
2019 |
2018 |
2017 |
||||||||||
Contracted managed care |
% | % | % | |||||||||
Government |
% | % | % | |||||||||
Other third-parties |
% | % | % | |||||||||
Private-pay patients |
% | % | % | |||||||||
% | % | % | ||||||||||
5. |
Property and Equipment: |
December 31, |
||||||||
2019 |
2018 |
|||||||
Building |
$ | $ | ||||||
Land |
||||||||
Equipment and other |
||||||||
Accumulated depreciation |
( |
) | ( |
) | ||||
$ | $ | |||||||
6. |
Business Acquisitions: |
7. |
Goodwill and Intangible Assets: |
December 31, 2019 |
||||||||||||
Gross Carrying Value |
Accumulated Amortization |
Net Carrying Value |
||||||||||
Physician and hospital agreements |
$ | $ | ( |
) | $ | |||||||
Customer relationships |
( |
) | ||||||||||
Trade names |
( |
) | ||||||||||
Patented and other technology |
( |
) | ||||||||||
$ | $ | ( |
) | $ | ||||||||
December 31, 2018 |
||||||||||||
Gross Carrying Value |
Accumulated Amortization |
Net Carrying Value |
||||||||||
Physician and hospital agreements |
$ | $ | ( |
) | $ | |||||||
Customer relationships |
( |
) | ||||||||||
Trade names |
( |
) | ||||||||||
Patented and other technology |
( |
) | ||||||||||
$ | $ | ( |
) | $ | ||||||||
2020 |
$ | |||
2021 |
||||
2022 |
||||
2023 |
||||
2024 |
8. |
Discontinued Operations: |
December 31, 2018 |
||||
Assets |
||||
Cash and cash equivalents |
$ | |||
Accounts receivable, net |
||||
Prepaid expenses and other assets |
||||
Property and equipment, net |
||||
Goodwill |
||||
Intangible assets, net |
||||
$ | ||||
Liabilities |
||||
Accounts payable, accrued expenses and other liabilities |
$ | |||
Deferred income taxes |
||||
$ | ||||
9. |
Accounts Payable and Accrued Expenses: |
December 31, |
||||||||
2019 |
2018 |
|||||||
Accounts payable |
$ | $ | ||||||
Accrued salaries and bonuses |
||||||||
Accrued payroll taxes and benefits |
||||||||
Accrued professional liabilities |
||||||||
Accrued contingent consideration |
||||||||
Accrued interest |
||||||||
Other accrued expenses |
||||||||
$ | $ | |||||||
10. |
Operating Leases: |
December 31, 2019 |
||||
Assets: |
||||
Operating lease right-of-use assets |
$ | |||
Liabilities: |
||||
Current portion of operating lease liabilities |
||||
Long-term portion of operating lease liabilities |
||||
Other Information: |
||||
Weighted-average remaining lease term |
||||
Weighted average discount rate |
% |
Year Ended December 31, 2019 |
||||
Operating lease costs |
$ | |||
Variable lease costs |
||||
Other equipment rent |
||||
Other operating lease costs |
||||
Total operating lease costs |
$ | |||
December 31, 2019 |
||||
Operating cash flows for operating leases |
$ |
December 31, 2019 |
||||
2020 |
$ | |||
2021 |
||||
2022 |
||||
2023 |
||||
2024 |
||||
Thereafter |
||||
Total minimum lease payments |
||||
Less: Amount of payments representing interest |
( |
) | ||
Present value of future minimum lease payments |
||||
Less: Current obligations |
( |
) | ||
Long-term portion of operating leases |
$ | |||
11. |
Accrued Professional Liabilities: |
Years Ended December 31, |
||||||||||||
2019 |
2018 |
2017 |
||||||||||
Balance at beginning of year |
$ | $ | $ | |||||||||
Assumed liabilities through acquisition |
||||||||||||
Provision (adjustment) for losses related to: |
||||||||||||
Current year |
||||||||||||
Prior years |
||||||||||||
Total provision for losses |
||||||||||||
Claim payments related to: |
||||||||||||
Current year |
( |
) | ( |
) | ( |
) | ||||||
Prior years |
( |
) | ( |
) | ( |
) | ||||||
Total payments |
( |
) | ( |
) | ( |
) | ||||||
Balance at end of year |
$ | $ | $ | |||||||||
12. |
Line of Credit, Long-Term Debt and Finance Lease Obligations: |
December 31, 2019 |
||||||||||||
Principal |
Unamortized Debt Issuance Costs |
Total |
||||||||||
Senior n otes |
$ | $ | ( |
) | $ |
|||||||
Revolving line of credit |
— |
( |
) | ( |
) | |||||||
Total |
$ | $ | ( |
) | $ | |||||||
December 31, 2018 |
||||||||||||
Principal |
Unamortized Debt Issuance Costs |
Total |
||||||||||
Senior n otes |
$ | $ | ( |
) | $ | |||||||
Revolving line of credit |
( |
) | ||||||||||
Total |
$ |
$ | ( |
) | $ | |||||||
December 31, |
||||||||
2019 |
2018 |
|||||||
2023 Notes |
$ | $ | ||||||
2027 Notes |
December 31, |
||||||||
2019 |
2018 |
|||||||
Finance lease obligations |
$ | $ | ||||||
Less: Current portion |
( |
) | ( |
) | ||||
Long-term portion |
$ | $ | ||||||
13. |
Income Taxes: |
December 31, |
||||||||||||
2019 |
2018 |
2017 |
||||||||||
Federal: |
||||||||||||
Current |
$ | $ | $ | |||||||||
Deferred |
( |
) | ( |
) | ( |
) | ||||||
( |
) | |||||||||||
State: |
||||||||||||
Current |
||||||||||||
Deferred |
( |
) | ( |
) | ||||||||
( |
) | |||||||||||
Total |
$ | ( |
) | $ | $ | |||||||
December 31, |
||||||||||||
2019 |
2018 |
2017 |
||||||||||
Tax at statutory rate |
% | % | % | |||||||||
State income tax, net of federal benefit |
||||||||||||
Non-deductible expenses |
( |
) | ||||||||||
Change in accrual estimates relating to uncertain tax positions |
— |
|||||||||||
Capital loss on liquidation |
— |
— |
||||||||||
Change in valuation allowance |
( |
) |
— |
— |
||||||||
Impairments |
( |
) |
— |
— | ||||||||
Other, net |
( |
) | ||||||||||
Change in tax law |
— |
( |
) | ( |
) | |||||||
Income tax provision |
% | % | % | |||||||||
December 31, |
||||||||
2019 |
2018 |
|||||||
Allowance for uncollectible accounts |
$ | $ | ||||||
Reserves and accruals |
||||||||
Stock-based compensation |
||||||||
Loss carryforwards |
||||||||
Property and equipment |
||||||||
Other |
||||||||
Deferred tax assets before valuation allowance |
||||||||
Less: Valuation allowance |
( |
) | ( |
) | ||||
Deferred tax assets, net of valuation allowance |
||||||||
Gross deferred tax liabilities: |
||||||||
Amortization |
( |
) | ( |
) | ||||
Accounting method changes |
( |
) | ( |
) | ||||
Accrual to cash adjustment |
— |
( |
) | |||||
Other |
( |
) | ( |
) | ||||
Total deferred tax liabilities |
( |
) | ( |
) | ||||
Net deferred tax assets ( liabilities ) |
$ | $ | ( |
) | ||||
Years Ended December 31, |
||||||||||||
2019 |
2018 |
2017 |
||||||||||
Balance at beginning of year |
$ | |
$ | |
$ | |
||||||
Increases related to prior year tax positions |
|
|
|
|||||||||
Decreases related to prior year tax positions |
— |
— |
( |
) | ||||||||
Increases related to current year tax positions |
|
|
|
|||||||||
Decreases related to lapse of statutes of limitation |
( |
) | ( |
) | ( |
) | ||||||
Balance at end of year |
$ | |
$ |
|
$ | |
||||||
14. |
Common and Common Equivalent Shares: |
Years Ended December 31, |
||||||||||||
2019 |
2018 |
2017 |
||||||||||
Weighted average number of common shares outstanding |
|
|
|
|||||||||
Weighted average number of dilutive common share equivalents (a) |
— |
|
|
|||||||||
Weighted average number of common and common equivalent shares outstanding |
|
|
|
|||||||||
Antidilutive securities not included in the diluted net income per common share calculation |
|
|
|
|||||||||
(a) |
Due to a loss for the year ended December 31, 2019, no incremental shares are included because the effect would be antidilutive. |
15. |
Stock Incentive Plans and Stock Purchase Plans: |
Number of Shares |
Weighted Average Fair Value |
|||||||
Non-vested shares at January 1, 2019 |
|
$ | |
|||||
Awarded |
|
$ | |
|||||
Forfeited |
( |
) | $ | |
||||
Vested |
( |
) | $ | |
||||
Non-vested shares at December 31, 2019 |
|
$ | |
|||||
Number of Stock Options |
Weighted Average Exercise Price |
Weighted Average Remaining Contractual Term (in years) |
Aggregate Intrinsic Value (in millions) |
|||||||||||||
Outstanding at January 1, 2019 |
|
$ | |
|||||||||||||
Exercised |
( |
) | $ | |
$ | |
||||||||||
Outstanding and exercisable at December 31, 2019 |
|
$ | |
|
$ | — |
||||||||||
16. |
Common Stock Repurchase Programs: |
17. |
Retirement Plans: |
18. |
Commitments and Contingencies: |
19. |
Selected Quarterly Financial Information (Unaudited): |
2019 Quarters |
||||||||||||||||
First |
Second |
Third |
Fourth |
|||||||||||||
Net revenue |
$ | $ |
$ | $ | ||||||||||||
Operating expenses: |
||||||||||||||||
Practice salaries and benefits |
||||||||||||||||
Practice supplies and other operating expenses |
||||||||||||||||
General and administrative expenses |
||||||||||||||||
Depreciation and amortization |
||||||||||||||||
Transformational and restructuring related expenses |
||||||||||||||||
Goodwill impairment |
— |
— |
— |
|||||||||||||
Total operating expenses |
||||||||||||||||
Income (loss) from operations |
( |
) | ||||||||||||||
Investment and other income |
||||||||||||||||
Interest expense |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Equity in earnings of unconsolidated affiliates |
||||||||||||||||
Total non-operating expenses |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Income (loss) from continuing operations before income taxes |
( |
) | ||||||||||||||
Income tax (provision) benefit |
( |
) | ( |
) | ( |
) | ||||||||||
Income (loss) from continuing operations |
( |
) | ||||||||||||||
(Loss) income from discontinued operations, net of tax |
( |
) | ( |
) | ( |
) | ||||||||||
Net (loss) income |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ||||||
Per common and common equivalent share data (1): |
||||||||||||||||
Income (loss) from continuing operations: |
||||||||||||||||
Basic |
$ | $ | $ | ( |
) | $ | ||||||||||
Diluted |
$ | $ | $ | ( |
) | $ | ||||||||||
(Loss) income from discontinued operations: |
||||||||||||||||
Basic |
$ | ( |
) | $ | ( |
) | $ | $ | ( |
) | ||||||
Diluted |
$ | ( |
) | $ | ( |
) | $ | $ | ( |
) | ||||||
Net (loss) income: |
||||||||||||||||
Basic |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ||||||
Diluted |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ||||||
Weighted average common shares: |
||||||||||||||||
Basic |
||||||||||||||||
Diluted |
||||||||||||||||
(1) | Basic and diluted per share amounts are computed for each of the periods presented. Accordingly, the sum of the quarterly per share amounts may not agree with the full year amount. |
2018 Quarters |
||||||||||||||||
First |
Second |
Third |
Fourth |
|||||||||||||
Net revenue |
$ | $ | $ | |||||||||||||
Operating expenses: |
||||||||||||||||
Practice salaries and benefits |
||||||||||||||||
Practice supplies and other operating expenses |
||||||||||||||||
General and administrative expenses |
||||||||||||||||
Depreciation and amortization |
||||||||||||||||
Total operating expenses |
||||||||||||||||
Income from operations |
||||||||||||||||
Investment and other income |
||||||||||||||||
Interest expense |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Equity in earnings of unconsolidated affiliates |
||||||||||||||||
Total non-operating expenses |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Income from continuing operations before income taxes |
||||||||||||||||
Income tax provision |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
Income from continuing operations |
||||||||||||||||
Income (loss) from discontinued operations, net of tax |
( |
) | ||||||||||||||
Net income |
$ | $ | $ | |||||||||||||
Per common and common equivalent share data (2): |
||||||||||||||||
Income from continuing operations: |
||||||||||||||||
Basic |
$ | $ | $ | $ | ||||||||||||
Diluted |
$ | $ | $ | $ | ||||||||||||
Income (loss) from discontinued operations: |
||||||||||||||||
Basic |
$ | $ | $ | $ | ( |
) | ||||||||||
Diluted |
$ | $ | $ | $ | ( |
) | ||||||||||
Net income: |
||||||||||||||||
Basic |
$ | $ | $ | $ | ||||||||||||
Diluted |
$ | $ | $ | $ | ||||||||||||
Weighted average common shares: |
||||||||||||||||
Basic |
||||||||||||||||
Diluted |
||||||||||||||||
(2) | Basic and diluted per share amounts are computed for each of the periods presented. Accordingly, the sum of the quarterly per share amounts may not agree with the full year amount. |
ITEM 9. |
CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE |
ITEM 9A. |
CONTROLS AND PROCEDURES |
ITEM 9B. |
OTHER INFORMATION |
ITEM 10. |
DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE |
ITEM 11. |
EXECUTIVE COMPENSATION |
ITEM 12. |
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS |
Plan Category |
Number of securities to be issued upon exercise of outstanding options, warrants and rights |
Weighted-average exerciseprice of outstanding options, warrants and rights |
Number of securities remaining available for future issuance under equity compensation plans (excluding securities reflected in column (a)) |
|||||||||
(a) |
(b) |
(c) |
||||||||||
Equity compensation plans approved by security holders |
72,808 |
(1) | $ | 32.49 |
9,404,824 |
(2) | ||||||
Equity compensation plans not approved by security holders |
N/A |
N/A |
N/A |
|||||||||
Total |
72,808 |
$ | 32.49 |
9,404,824 |
||||||||
(1) | All shares are issuable under the Amended and Restated 2008 Incentive Plan. |
(2) | Under the Amended and Restated 2008 Incentive Plan, 8,321,355 shares remain available for future issuance, and under the ESPP and the SPP, an aggregate of 1,083,469 shares remain available for future issuance. |
ITEM 13. |
CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE |
ITEM 14. |
PRINCIPAL ACCOUNTING FEES AND SERVICES |
ITEM 15. |
EXHIBITS AND FINANCIAL STATEMENT SCHEDULE |
Years Ended December 31, |
||||||||||||
2019 |
2018 |
2017 |
||||||||||
Allowance for contractual adjustments and uncollectibles: |
||||||||||||
Balance at beginning of year |
$ | 1,486,672 |
$ | 1,284,565 |
$ | 1,222,998 |
||||||
Amount charged against operating revenue |
9,383,853 |
8,944,637 |
8,285,317 |
|||||||||
Accounts receivable contractual adjustments and write-offs (net of recoveries) |
(9,425,730 |
) | (8,742,530 |
) | (8,223,750 |
) | ||||||
Balance at end of year |
$ | 1,444,795 |
$ | 1,486,672 |
$ | 1,284,565 |
||||||
(a)(3) |
Exhibits |
(b) |
Exhibits |
2.1 |
||||
2.2** |
||||
3.1 |
||||
3.2 |
||||
4.1 |
||||
4.2 |
4.3 |
||||
4.4 |
||||
4.5 |
||||
4.6 |
||||
4.7 |
||||
4.8 |
||||
4.9 |
||||
4.10+ |
||||
10.1 |
||||
10.2 |
10.3 |
||||
10.4 |
||||
10.5 |
||||
10.6 |
||||
10.7 |
||||
10.8 |
||||
10.9 |
||||
10.10 |
||||
10.11 |
||||
10.12 |
||||
10.13 |
||||
10.14 |
||||
10.15 |
||||
10.16 |
||||
10.17 |
10.18 |
||||
10.19 |
||||
10.20 |
||||
10.21 |
||||
10.22 |
||||
10.23 |
||||
10.24 |
||||
10.25+ |
||||
10.26 |
||||
10.27 |
||||
21.1+ |
||||
23.1+ |
||||
31.1+ |
||||
31.2+ |
||||
32++ |
||||
101.1+ |
Inline Interactive Data File | |||
101.INS+ |
Inline XBRL Instance Document—the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document. | |||
101.SCH+ |
Inline XBRL Schema Document. | |||
101.CAL+ |
Inline XBRL Calculation Linkbase Document. |
101.DEF+ |
Inline XBRL Definition Linkbase Document. | |||
101.LAB+ |
Inline XBRL Label Linkbase Document. | |||
101.PRE+ |
Inline XBRL Presentation Linkbase Document. | |||
104+ |
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101). |
* | Management contracts or compensation plans, contracts or arrangements. |
** | Portions of this exhibit have been omitted pursuant to Item 601(b)(2) of Regulation S-K because they are both (i) not material and (ii) would likely cause competitive harm to the registrant if publicly disclosed. The schedules and similar attachments to this exhibit have been omitted pursuant to Item 601(a)(5) of Regulation S-K. |
+ | Filed herewith. |
++ | Furnished herewith. |
ITEM 16. |
FORM 10-K SUMMARY |
MEDNAX, INC. | ||||||
Date: February 20, 2020 |
By: |
/s/ Roger J. Medel, M.D. | ||||
Roger J. Medel, M.D. | ||||||
Chief Executive Officer |
Signature |
Title |
Date | ||
/s/ Roger J. Medel, M.D. Roger J. Medel, M.D. |
Chief Executive Officer, Director (Principal Executive Officer) |
February 20, 2020 | ||
/s/ Stephen D. Farber Stephen D. Farber |
Executive Vice President and Chief Financial Officer (Principal Financial Officer) |
February 20, 2020 | ||
/s/ John C. Pepia John C. Pepia |
Senior Vice President and Chief Accounting Officer (Principal Accounting Officer) |
February 20, 2020 | ||
/s/ Cesar L. Alvarez Cesar L. Alvarez |
Director and Chairman of the Board |
February 20, 2020 | ||
/s/ Manuel Kadre Manuel Kadre |
Lead Independent Director |
February 20, 2020 | ||
/s/ Karey D. Barker Karey D. Barker |
Director |
February 20, 2020 | ||
/s/ Waldemar A. Carlo, M.D. Waldemar A. Carlo, M.D. |
Director |
February 20, 2020 | ||
/s/ Michael B. Fernandez Michael B. Fernandez |
Director |
February 20, 2020 | ||
/s/ Paul G. Gabos Paul G. Gabos |
Director |
February 20, 2020 | ||
/s/ Pascal J. Goldschmidt, M.D. Pascal J. Goldschmidt, M.D. |
Director |
February 20, 2020 | ||
/s/ Carlos A. Migoya Carlos A. Migoya |
Director |
February 20, 2020 | ||
/s/ Michael A. Rucker Michael A. Rucker |
Director |
February 20, 2020 | ||
/s/ Enrique J. Sosa, Ph.D. Enrique J. Sosa, Ph.D. |
Director |
February 20, 2020 |
Exhibit 4.10
DESCRIPTION OF THE REGISTRANTS SECURITIES REGISTERED PURSUANT TO SECTION 12
OF THE SECURITIES EXCHANGE ACT OF 1934
As of December 31, 2019, the only class of securities of MEDNAX, Inc., a Florida corporation (the Company), registered under Section 12 of the Securities Exchange Act of 1934, as amended, is common stock, par value $0.01 per share (Common Stock). The Common Stock is listed on the New York Stock Exchange under the symbol MD.
Overview
The following summarizes certain material terms and provisions of the Common Stock. It does not purport to be complete, however, and is qualified in its entirety by reference to Florida law and by the actual terms and provisions contained in the Companys Amended and Restated Articles of Incorporation, as amended (the Articles), and the Companys Amended and Restated Bylaws (the Bylaws).
The Articles authorize the Companys board of directors (the Board of Directors) to issue up to 200,000,000 shares of Common Stock and 1,000,000 shares of preferred stock, par value $0.01 per share. As of February 14, 2020, there were 84,277,494 shares of Common Stock issued and outstanding and no shares of preferred stock issued and outstanding. All issued and outstanding shares of Common Stock are duly issued, fully paid and nonassessable.
General Description of Common Stock
Each share of Common Stock entitles its owner to one vote on all matters submitted to a vote of the Companys shareholders. Subject to the rights of the holders of the Companys preferred stock, the holders of Common Stock are entitled to receive dividends, when, as and if declared by the Board of Directors, in its discretion, from funds legally available for the payment of dividends, payable in cash, stock or otherwise. If the Company liquidates, dissolves or winds-up, whether voluntarily or involuntarily, the holders of Common Stock, to the exclusion of the holders of the Companys preferred stock, will be entitled to share proportionately in the Companys assets, if any, legally available for distribution to shareholders, but only after the Company has paid all of its debts and liabilities and after the holders of the Companys preferred stock have been paid in full the amounts to which they are entitled, if any, or a sum sufficient for such payment has been set aside.
The Common Stock has no preemptive rights, no sinking fund provisions and no subscription, redemption or conversion privileges, and it is not subject to any further calls or assessments by the Company. The Common Stock does not have cumulative voting rights. Moreover, directors are elected by a plurality of the votes cast by the shares entitled to vote in the election at a meeting in which a quorum is present; however, the Board of Directors adopted in 2012 a majority vote policy as part of the Companys corporate governance principles which provides that, in uncontested elections, which are those elections in which the number of nominees for election is less than or equal to the number of directors to be elected, any nominee for director who receives more withheld votes than for votes must submit a written offer to resign as director. Any such resignation will be reviewed by the Nominating and Corporate Governance Committee of the Board of Directors and, within 90 days after the election, the independent members of the Board of Directors will determine whether to accept, reject or take other appropriate action with respect to, the resignation, in furtherance of the best interests of the Company and its shareholders.
General Description of Preferred Stock
The Articles authorize the Board of Directors, without further shareholder approval, to:
| issue preferred stock in one or more class or series; |
| establish the number of shares to be included in each such class or series, including increasing and decreasing the number of shares of preferred stock designated for any existing class or series; and |
| fix the designations, powers, preferences and rights of the shares of each class or series and any qualifications, limitations or restrictions on those shares. |
The Board of Directors may establish a class or series of preferred stock with preferences, powers and rights (including voting rights) senior to the rights of the holders of Common Stock. If the Company issues any preferred stock, it may have the effect of delaying, deferring or preventing a change in control.
The Articles of Amendment Designating Series A Junior Participating Preferred Stock designate 50,000 shares of preferred stock as Series A Junior Participating Preferred Stock, par value $0.01 per share (Series A Preferred). As of February 14, 2020, no shares of Series A Preferred were outstanding. Subject to the rights of the holders of preferred stock senior to the Series A Preferred, if any, and certain other conditions, the holders of Series A Preferred will be entitled to receive cumulative quarterly dividends, when, as and if declared by the Board of Directors, in its discretion, from funds legally available for the payment of dividends. Each share of Series A Preferred will be entitled to a minimum preferential quarterly dividend payment of $1.00 per share but will be entitled to an aggregate dividend of 2,000 times the dividend declared per share of Common Stock. Each share of Series A Preferred entitles the holder thereof to 2,000 votes on all matters submitted to a vote of the Companys shareholders and the Series A Preferred vote together with Common Stock as one class, unless otherwise required by any future articles of designation or by law. Notwithstanding the foregoing, the holders of Series A Preferred have no special voting rights and their consent is not required for taking any corporate action, except to the extent set forth in the Articles of Amendment Designating Series A Junior Participating Preferred Stock. In the event of liquidation, the holders of Series A Preferred will be entitled to a minimum preferential liquidation payment of $1.00 per share but will be entitled to an aggregate payment of 2,000 times the payment made per share of Common Stock. Finally, in the event of any merger, consolidation or other transaction in which Common Stock is exchanged, each share of Series A Preferred will be entitled to receive 2,000 times the amount received per share of Common Stock. These rights are protected by customary antidilution provisions.
If shares of Series A Preferred were to be issued, the voting and consent rights provided in the Articles of Amendment Designating Series A Junior Participating Preferred Stock may have the effect of delaying, deferring or preventing a change in control of the Company. The Series A Preferred has no preemptive rights, no sinking fund provisions and no subscription, redemption or conversion privileges, and it is not subject to any further calls or assessments by the Company. In addition, the Series A Preferred must rank, with respect to the payment of dividends and the distribution of assets, junior to all series of any other class of the preferred stock.
Material Provisions of the Companys Amended and Restated Articles of Incorporation and Amended and Restated Bylaws
The Articles and Bylaws contain material provisions that may make the acquisition of control of the Company more difficult.
Classified Board of Directors and Related Provisions. The Articles and Bylaws provide that the number of directors will be established from time to time by resolution of the Board of Directors. The Bylaws also provide that the Board of Directors may be divided into two or more classes of directors. Although the Board of Directors is not currently classified, a classified Board of Directors could prevent a party who acquires control of a majority of the Companys outstanding voting stock from obtaining control of the Board of Directors until annual shareholders meeting following the date on which the acquirer obtains its controlling interest.
The Articles provide that the Companys shareholders may only remove a director from office prior to the expiration of his or her term if such removal is for cause and only by an affirmative vote of two-thirds of all of the Companys outstanding capital stock entitled to vote for the election of directors. If there is a vacancy on the Board of Directors, a majority of the Companys remaining directors, although less than a quorum of the entire Board of Directors, may fill such vacancy for the unexpired term of his or her predecessor, or until the next election of one or more directors by the Companys shareholders if the vacancy is caused by an increase in the size of the Board of Directors. The Companys shareholders may not fill any vacancy on the Board of Directors.
Shareholder Action By Written Consent. The Bylaws provide that any actions which the Companys shareholders may take at a shareholders meeting can be taken by written consent in lieu of a meeting. In order to effect a shareholder action by written consent in lieu of a meeting, holders of the Companys outstanding voting stock, having at least the minimum number of votes that would be necessary to authorize the action at a shareholders meeting, must sign a written consent which states the action to be taken. If the shareholders take any action by written consent in lieu of a meeting, the Company must notify all of its shareholders that did not consent to the action in writing or that were not entitled to vote on the action within 10 days after receiving the written consent and describe the action to them.
Shareholder-Proposed Business. In addition to any other applicable requirements, for business to be properly brought by a shareholder before an annual meeting of the shareholders, the Articles require that such shareholder give timely notice thereof in writing to the Companys Secretary. If such notice is not timely given, the shareholder-proposed business will not be brought before such annual meeting. To be timely, a shareholders notice must be delivered to or mailed and received at the Companys principal executive offices neither less than 120 days nor more than 180 days prior to the first anniversary of the date of the Companys notice of annual meeting provided to shareholders with respect to the previous years annual meeting. If no annual meeting of shareholders was held in the previous year or the date of the current years annual meeting has been changed to be more than 30 calendar days earlier than the date contemplated by the previous years proxy statement, such shareholders notice must be so delivered or received no later than the close of business on the tenth day following the date on which notice the current years annual meeting is given to shareholders or made public, whichever occurs first.
Indemnification. The Articles provide that the Company shall indemnify, and may advance expenses to, its officers and directors to the fullest extent permitted by law.
Florida Anti-Takeover Statute
As a Florida corporation, the Company is subject to certain anti-takeover provisions that apply to public corporations under Florida law. Pursuant to Section 607.0901 of the Florida Business Corporation Act (the Florida Act), a publicly held Florida corporation may not engage in a broad range of business combinations or other extraordinary corporate transactions with an interested shareholder without the approval of the holders of two-thirds of the voting shares of the corporation (excluding shares held by the interested shareholder), unless, among other exceptions:
| the transaction is approved by a majority of disinterested directors; |
| the interested shareholder has owned at least 80% of the corporations outstanding voting shares for at least five years preceding the announcement date of any such business combination; |
| the interested shareholder is the beneficial owner of at least 90% of the outstanding voting shares of the corporation, exclusive of shares acquired directly from the corporation in a transaction not approved by a majority of the disinterested directors; or |
| the consideration paid to the holders of the corporations voting stock is at least equal to certain fair price criteria. |
Subject to certain exceptions, an interested shareholder is defined as a person who together with affiliates and associates beneficially owns more than 10% of a corporations outstanding voting shares. Although permitted by the Florida Act, the Company has not made an election in its Articles to opt out of Section 607.0901.
In addition, the Company is subject to Section 607.0902 of the Florida Act which prohibits the voting of shares in a publicly held Florida corporation that are acquired in a control share acquisition unless (i) the Board of Directors approved such acquisition prior to its consummation or (ii) after such acquisition, in lieu of prior approval by the Board of Directors, the holders of a majority of the corporations voting shares, exclusive of shares owned by officers of the corporation, employee directors or the acquiring party, approve the granting of voting rights as to the shares acquired in the control share acquisition. A control share acquisition is defined as an acquisition that immediately thereafter entitles the acquiring party to 20% or more of the total voting power in an election of directors.
Exhibit 10.25
EMPLOYMENT AGREEMENT
THIS EMPLOYMENT AGREEMENT (this Agreement) is made and entered into by and between MEDNAX SERVICES, INC., a Florida corporation (Employer) and JOHN C. PEPIA (Employee) effective as the Effective Date.
RECITALS
WHEREAS, Employer is presently engaged in Employers Business as defined on Exhibit A hereto; and
WHEREAS, Employer desires to continue to employ Employee and benefit from Employees contributions to Employer; and
WHEREAS, Employee has previously served in various management positions with the Employer, and its predecessor company, and was promoted to Chief Accounting Officer of Employer in August 2016; and
WHEREAS, Employer and Employee previously entered in an Employment Agreement dated January 1, 2004, as amended (the Prior Employment Agreement); which will be superseded in its entirety upon execution of this Agreement; and
WHEREAS, in order to induce Employer to enter into this Agreement on the terms and conditions set forth herein, and disclose its trade secrets and confidential information in connection with Employees employment by Employer and award from time to time equity based compensation, Employee hereby agrees to be bound by the terms of this Agreement, including the arbitration, non-competition and related restrictive covenants set forth herein.
NOW, THEREFORE, in consideration of the premises and mutual covenants set forth herein, the parties agree as follows:
1. Employment.
1.1. Employment and Term. Employer hereby agrees to employ Employee and Employee hereby agrees to serve Employer on the terms and conditions set forth herein for an Initial Term commencing August 1, 2019 (the Effective Date) and continuing for a period of three (3) years, unless sooner terminated as hereinafter set forth. Thereafter, the employment of Employee hereunder shall automatically renew for successive one (1) year periods until terminated in accordance herewith. The Initial Term and any automatic renewals shall be referred to as the Employment Period.
1.2. Duties of Employee. During the Employment Period, Employee shall serve as Senior Vice President, Chief Accounting Officer of Employer and perform such duties as are customary to the position Employee holds or as may be assigned to Employee from time to time by Employees supervisor (Employees Supervisor); provided, that such duties as assigned shall be
customary to Employees role as an officer of Employer. Employees employment shall be full-time and as such Employee agrees to devote substantially all of Employees attention and professional time to the business and affairs of Employer. Employee shall perform Employees duties honestly, diligently, competently, in good faith and in the best interest of Employer. Employee will devote best efforts to the promotion of the goodwill of Employer and of its employees and affiliates. During the Employment Term, Employer shall promote the proficiency of Employee by, among other things, providing Employee with Confidential Information, specialized professional development programs, and information regarding the organization, administration and operation of Employer. During the Employment Period, Employee agrees that Employee will not, without the prior written consent of Employer (which consent shall not be unreasonably withheld), serve as a director on a corporate board of directors or in any other similar capacity for any institution other than Employer. During the Employment Period, it shall not be a violation of this Agreement to (i) serve on civic or charitable boards or committees, or (ii) deliver lectures, fulfill speaking engagements or teach at educational institutions, so long as such activities have been approved by Employees Supervisor and do not interfere with the performance of Employees responsibilities as an employee of Employer in accordance with this Agreement, including the restrictions of Section 8 hereof.
1.3. Place of Performance. Employee shall be based at Employers offices located in Sunrise, Florida, except for required travel relating to Employers Business.
2. Base Salary-and Performance Bonus.
2.1. Base Salary. Employee shall be paid an annual base salary as determined by Employees supervisor from time to time (the Base Salary), payable in installments consistent with Employers customary payroll schedule and subject to applicable withholding for taxes and other Employee directed withholdings. Any increase to Employees Base Salary that is approved by Employees Supervisor shall become Employees new Base Salary for purposes of this Agreement.
2.2. Performance Bonus. Employee shall be eligible for an annual bonus of up to the amount set forth on Exhibit B (the Performance Bonus). The amount of the actual bonus paid to Employee, if any, shall be based upon the achievement of specific objectives to be developed and agreed upon by Employee and Employees Supervisor each year and the performance of Employer. Except in the situations described in Sections 4.1(d), 5.2, 5.3, 5.4, 5.5 and 5.7, the Performance Bonus shall only be payable to Employee if Employee is employed with Employer as of the date that the Performance Bonus is paid by Employer. Each Performance Bonus shall be paid in the calendar year immediately following the calendar year in which it is earned, as soon as practicable after the audited financial statements for Employer for the year for which the bonus is earned have been released; provided, however, that if calculation of Employees Performance Bonus is not administratively practicable due to events beyond the control of Employer, then Employer may delay payment of the Performance Bonus provided that the payment is made during the first taxable year of Employee in which the calculation of the amount of the payment is administratively practicable.
2
3. Benefits.
3.1. Expense Reimbursement. Employer shall promptly reimburse Employee for all out-of-pocket expenses reasonably incurred by Employee during the Employment Period on behalf of or in connection with Employers Business pursuant to the reimbursement standards and guidelines of Employer in effect from time to time. Employee shall account for such expenses and submit reasonable supporting documentation to Employer in accordance with Employers policies in effect from time to time.
3.2 Employee Benefits. During the Employment Period, Employee shall be entitled to participate in such health, welfare, disability, retirement savings and other fringe benefit plans and programs (subject to the terms and conditions of such plans and programs) as may be provided from time to time to employees of Employer and to the extent that such plans and programs are applicable to other similarly situated employees of Employer.
3.3. Leave Time. During the Employment Period, Employee shall be entitled to paid vacation and leave days each calendar year in accordance with the leave policies established by Employer from time to time. Any leave time not used during each fiscal year of Employer may be carried over into the next year to the extent permitted by Employer policy.
3.4 Equity Plans. During the Employment Period, Employee shall be eligible to participate in MEDNAX, Inc.s Amended and Restated 2008 Incentive Compensation Plan or any other similar plan adopted by MEDNAX, Inc. (each an Equity Plan) that provides for the issuance of stock options, stock appreciation rights, restricted stock, deferred stock, bonus stock, awards payable in stock or any other stock based award (each an Equity Award). Employees stock-based award each year shall be determined by the Compensation Committee of MEDNAX, Inc.s Board of Directors based on Employees performance and Employers performance during the immediately preceding year. Every Equity Award made to Employee shall be subject to the terms and conditions of this Agreement, the applicable award agreement and the terms of the Equity Plan. Employee shall also be eligible to participate in MEDNAX, Inc.s non-qualified employee stock purchase plan and any successor plan. Employee acknowledges Employees participation in the Equity Plan pursuant to this Section 3 is sufficient consideration for Employee to enter into this Agreement, including the restrictive covenants set forth in Section 8 below.
4. Termination.
4.1. Termination for Cause. Employer may terminate Employees employment under this Agreement for Cause. As used in this Agreement, the term Cause shall mean:
(a) Any act or omission of Employee, which is materially contrary (having reference to corporate and industry custom and standards) to the business interests, reputation or goodwill of Employer;
(b) A material breach by Employee of Employees obligations under this Agreement, which breach is not promptly remedied upon written notice from Employer;
3
(c) Employees refusal to perform Employees duties as assigned pursuant to this Agreement other than a refusal which is remedied by Employee promptly after receipt of written notice thereof by Employer;
(d) The determination by Employer made in good faith that Employees performance of Employees duties hereunder is below Employers standards for Employees position with Employer; provided, that Employer has first provided Employee with written notice setting forth the basis for Employers determination and Employee has failed to cure the matter(s) cited within thirty (30) days after receipt of notice; and provided, further, that if Employer provides such notice and Employee is able to cure the matter but is not able to sustain performance at an acceptable level, or, if such matter is incapable of cure, Employer may terminate Employee without further notice or opportunity to cure upon any future failure by Employee to perform Employees duties consistent with Employers standards; or
(e) Employees failure or refusal to comply with a reasonable policy, standard or regulation of Employer in any material respect, including but not limited to Employers sexual harassment, other unlawful harassment, workplace discrimination or substance abuse policies.
The termination date for a termination of Employees employment under this Agreement pursuant to this Section 4.1 shall be the date specified by Employer in a written notice to Employee of finding of Cause, which may not be retroactive. Upon any termination of Employees employment under this Agreement pursuant to this Section 4.1, Employee shall be entitled to the compensation specified in Section 5.1 hereof.
4.2. Disability. Employer may terminate Employees employment under this Agreement upon the Disability (as defined below) of Employee. Subject to the requirements of applicable law, Employee shall be deemed to have a Disability for purposes of this Agreement in the event of (i) Employees inability to perform Employees duties hereunder, with or without a reasonable accommodation, as a result of physical or mental illness or injury, and (ii) a determination by an independent qualified physician selected by Employer and acceptable to Employee (which acceptance shall not be unreasonably withheld) that Employee is currently unable to perform such duties and in all reasonable likelihood such inability will continue for a period in excess of an additional ninety (90) or more days in any one hundred twenty (120) day period. The termination date for a termination of this Agreement pursuant to this Section 4.2 shall be the date specified by Employer in a notice to Employee, which date shall not be retroactive. Upon any termination of this Agreement pursuant to this Section 4.2, Employee shall be entitled to compensation and/or benefits in accordance with, and subject to, the provisions of Section 5.2 hereof.
4.3. Death. Employees employment under this Agreement shall terminate automatically upon the death of Employee, without any requirement of notice by Employer to Employees estate. The date of Employees death shall be the termination date for a termination of Employees employment under this Agreement pursuant to this Section 4.3. Upon any termination of Employees employment under this Agreement pursuant to this Section 4.3, Employee shall be entitled to the compensation specified in Section 5.3 hereof.
4
4.4. Termination by Employer Without Cause. Employer may terminate Employees employment without cause by giving Employee written notice of such termination. The termination date shall be the date specified by Employer in such notice, which may be up to ninety (90) days from the date of such notice. Upon any termination of Employees employment under this Agreement pursuant to this Section 4.4, Employee shall be entitled to compensation and/or benefits in accordance with, and subject to, the provisions of Section 5.4 hereof.
4.5. Termination by Employee Due to Poor Health. Employee may terminate Employees employment under this Agreement upon written notice to Employer if Employees health should become impaired to any extent that makes the continued performance of Employees duties under this Agreement hazardous to Employees physical or mental health or Employees life (regardless of whether such condition would be deemed a Disability under any other Section of this Agreement), provided that Employee shall have furnished Employer with a written statement from a qualified doctor to that effect, and provided further that, at Employers written request and expense, Employee shall submit to a medical examination by an independent qualified physician selected by Employer and acceptable to Employee (which acceptance shall not be unreasonably withheld), which doctor shall substantially concur with the conclusions of Employees doctor. The termination date shall be the date specified in Employees notice to Employer, which date may not be earlier than thirty (30) days nor later than ninety (90) days from Employers receipt of such notice. Upon any termination of Employees employment under this Agreement pursuant to this Section 4.5, Employee shall be entitled to compensation and/or benefits in accordance with, and subject to, the provisions of Section 5.5 hereof.
4.6. Termination by Employee. Employee may terminate Employees employment under this Agreement for any reason whatsoever upon not less than ninety (90) days prior written notice to Employer. Upon receipt of such notice from Employee, Employer may, at its option, require Employee to terminate employment at any time in advance of the expiration of such ninety (90) day period. The termination date under this Section 4.6 shall be the date specified by Employer, but in no event more than ninety (90) days after Employers receipt of notice from Employee as contemplated by this Section. Upon any termination of Employees employment under this Agreement pursuant to this Section 4.6, Employee shall be entitled to compensation and/or benefits in accordance with, and subject to, the provisions of Section 5.6 hereof.
4.7. Termination by Employee for Good Reason. Employee may terminate Employees employment hereunder for Good Reason. For purposes of this Section, Good Reason shall mean:
(a) a decrease in Employees Base Salary;
(b) a decrease in the Performance Bonus potential utilized by Employer in determining a Performance Bonus for Employee; or
5
(c) within a twelve (12) month period after a Change in Control (as defined below), Employee is either (i) terminated pursuant to Section 4.4 or Employee terminates Employees employment pursuant to Section 4.7, (ii) assigned any position, duties, responsibilities or compensation that is inconsistent with the position, duties, responsibilities or compensation of Employee prior to such Change in Control, or (iii) required to perform services under this Agreement from another location more than twenty-five (25) miles from Employees location prior to the Change in Control. For purposes of this Agreement, Change in Control shall mean (i) the acquisition by a person or an entity or a group of persons and entities, directly or indirectly, of more than fifty (50%) percent of MEDNAX, Inc.s common stock in a single transaction or a series of transactions (hereinafter referred to as a 50% Change in Control), (ii) a merger or other form of corporate reorganization of MEDNAX, Inc. resulting in an actual or de facto 50% Change in Control, or (iii) the failure of Applicable Directors (defined below) to constitute a majority of MEDNAX, Inc.s Board of Directors (the Board) during any two (2) consecutive year period after the date of this Agreement (the Two-Year Period). Applicable Directors shall mean those individuals who are members of the Board at the inception of a Two-Year Period and any new director whose election to the Board or nomination for election to the Board was approved (prior to any vote thereon by the shareholders) by a vote of at least two-thirds (2/3) of the directors then still in office who either were directors at the beginning of the Two-Year Period at issue or whose election or nomination for election during such Two-Year Period was previously approved as provided in this sentence; or
(d) the assignment to Employee of any position inconsistent with the present position Employee holds, or material diminution in Employees authority, excluding for this purpose any isolated, insubstantial and inadvertent action not taken in bad faith and which is remedied by Employer promptly after receipt of written notice; or
(e) the requirement by Employer that Employee be based in any office or location outside of the metropolitan area where Employers present corporate offices are located (it being understood that Employee may be presently based at another location), except for travel reasonably required in the performance of Employees duties.
If Employee desires to terminate Employees employment under this Agreement pursuant to this Section, Employee must, within one hundred eighty (180) days after the occurrence of events giving rise to the Good Reason, provide Employer with a written notice describing the Good Reason in reasonable detail. If Employer fails to cure the matter cited within thirty (30) days after the date of Employees notice, then this Agreement shall terminate as of the end of such thirty (30) day cure period, provided, however, that Employer may, at its option, require Employee to terminate employment at any time in advance of the expiration of such thirty (30) day cure period. If Employee terminates Employees employment under this Agreement pursuant to this Section 4.7, then Employee shall be entitled to compensation and/or benefits in accordance with, and subject to, the provisions of Section 5.7 hereof.
5. Compensation and Benefits Upon Termination.
5.1. Cause. If Employees employment is terminated for Cause, Employer shall pay Employees Base Salary through the termination date specified in Section 4.1 at the rate in effect at the termination date. In addition, if Employees employment is terminated pursuant to Section 4.1(d), Employer shall continue Base Salary payments to Employee for a period of six (6) months after the termination date. Upon payment of such amounts, plus any amounts as may be due under Section 5.8 and 5.11 below, Employer shall have no further obligation to Employee under this Agreement.
6
5.2. Disability. In the event of Employees Disability, Employee shall continue to receive Employees Base Salary for the first ninety (90) days of Disability. If Employees employment is terminated pursuant to Section 4.2 in connection with Employees Disability, Employee shall receive fifty percent (50%) of Employees annual Base Salary at the rate in effect at the termination date, payable in six (6) equal monthly installments after the termination date, plus a bonus calculated in accordance with Section 5.11 and any amounts as may be due under Section 5.8 and 5.9.
5.3. Death. Upon Employees death during the Employment Period, Employer shall pay to the person or entity designated by Employee in a notice filed with Employer or, if no person is designated, to Employees estate any unpaid amounts of Base Salary to the date of Employees death, plus any amounts as may be due under Sections 5.8 and 5.11 below. Any payments Employees spouse, beneficiaries or estate may be entitled to receive pursuant to any pension plan, employee welfare benefit plan, life insurance policy, or similar plan or policy then maintained by Employer shall be determined and paid in accordance with the written instruments governing the respective plans and policies. In the event of Employees death during the Employment Period, Employer shall notify Employees designee or estate of the Equity Awards held by Employee and the procedures pursuant to which all vested stock options may be exercised and other Equity Awards may be realized under the terms applicable to such awards.
5.4. Termination by Employer Without Cause. If Employer terminates Employees employment in accordance with Section 4.4, then (i) Employer shall pay Employees Base Salary through the termination date specified in Section 4.4 at the rate in effect at such termination date, plus any amount due under Section 5.8 hereof; (ii) pay Employee a bonus calculated in accordance with Section 5.11 hereof; (iii) Employer shall continue to pay Employees monthly Base Salary for a period of twelve (12) months after the termination date (iv) within thirty (30) days of the first (1st) anniversary of the termination date, pay Employee an amount equal to the greater of Employees Average Annual Performance Bonus (as defined below) or Employees bonus for the year immediately preceding Employees termination; and (v)if applicable, Employee shall vest into the Accelerated Awards (as defined below) as set forth in Section 5.14 hereof. For purposes of this Agreement, Average Annual Performance Bonus shall be equal to the average of the percentage of the Performance Bonus target achieved by Employee for the three (3) full calendar years prior to the termination date, and calculated based on Employees Base Salary and target Performance Bonus in Employees current position.
5.5. Termination by Employee Due to Poor Health. If Employee terminates Employees employment under this Agreement pursuant to Section 4.5 hereof, Employer shall pay to Employee any unpaid amounts of Base Salary to the termination date specified in Section 4.5, plus any disability payments otherwise payable by or pursuant to plans provided by Employer, plus any amounts as may be due under Sections 5.8 and 5.11.
7
5.6. Termination by Employee. If Employees employment under this Agreement terminates pursuant to Section 4.6 hereof, Employer shall pay to Employee any unpaid amounts of Base Salary to the termination date specified in Section 4.6, plus any amounts as may be due under Section 5.8 below. In the event that the termination date specified by Employer is less than ninety (90) days after the date of Employers receipt of notice as contemplated by Section 4.6, then Employer shall continue Employees Base Salary for a period of days equal to ninety (90) minus the number of days from Employees notice to the termination date.
5.7. Termination for Good Reason. If Employees employment under this Agreement is terminated pursuant to Section 4.7, then Employer shall (i) pay Employees Base Salary through the termination date specified in Section 4.7 at the rate in effect at such termination date, (ii) pay any amounts as may be due under Section 5.8 and 5.11, (iii) continue to pay Employees Base Salary for a period of twelve (12) months after the termination date, and (iv) if applicable, Employee shall vest into the Accelerated Awards (as defined below) as set forth in Section 5.14 hereof. In addition, notwithstanding any contrary provision in any Equity Plan, in the event of Employees termination pursuant to Section 4.7(c), any unvested Equity Awards held by Employee on the termination date shall fully vest and in the case of stock options, become immediately exercisable.
5.8. Expense Reimbursement. Employee shall be entitled to reimbursement for reasonable business expenses incurred prior to the termination date, subject, however to the provisions of Section 3.1. Such reimbursement shall be made at the times and in accordance with Employers normal procedures for reimbursements.
5.9. Continuation of Benefit Plans. Employee shall be entitled to continuation of health, medical, hospitalization and other similar health insurance programs on the same basis as regular, full-time employees of Employer and their eligible dependents during the period that Employee is receiving Base Salary payments under Section 5 of this Agreement and, in all cases, as provided by any applicable law. Following such period of continued benefit plan coverage, Employee and each of his eligible dependents shall be entitled to elect for continuation of coverage provided pursuant to Section 601 et. seq. of the Employee Retirement Income Security Act of 1974, 29 USC §1101 (COBRA).
5.10 Period for Exercising Stock Options After Termination. Except as to incentive stock options granted in accordance with Section 422 of the Internal Revenue Code, after termination of Employees employment under this Agreement for any reason other than pursuant to Section 4.1, Employee shall be allowed a period of twelve months during which to exercise any vested options to purchase MEDNAX, Inc.s common stock or vested stock appreciation rights and realize any other vested Equity Awards that may be granted or made under any Equity Plan; provided, however, that in no event shall the period during which Employee may exercise any vested stock option or vested stock appreciation right be extended pursuant to this Section 5.10 to a date that is later than the earlier of (i) the latest date upon which the stock right could have expired by its original terms under any circumstances or (ii) the tenth (10th) anniversary of the original date of grant of the stock right. In all other respects, the terms of the applicable Equity Plan shall control the terms and conditions of any Equity Awards.
8
5.11. Performance Bonus. In the situations described in Sections 4.1(d), 5.2, 5.3, 5.4, 5.5 and 5.7, upon termination of this Agreement, Employee will be paid, solely in consideration of services rendered by Employee prior to termination, a bonus with respect to Employers fiscal year in which the termination date occurs, equal to the Performance Bonus, if any, that would have been payable to Employee, based on Employee and Employer meeting certain goals and objectives, for the fiscal year if Employees employment had not been terminated, multiplied by the number of days in the fiscal year prior to and including the date of termination and divided by three hundred sixty five (365). The amount of the Post-Termination Performance Bonus paid in the situations described in Sections 4.1(d), 5.2, 5.3, 5.4 5.5 and 5.7 shall be determined in good faith by Employer in its sole discretion at the time that Employer distributes bonuses to similarly situated employees. Any amount payable under this Section 5.11 shall be paid to Employee when Employer pays performance bonuses to its eligible employees, which shall be in the calendar year following the termination date of this Agreement. In addition, in the situations described in Section 5.7, Employee will be paid, solely in consideration of services rendered by Employee prior to termination, an additional bonus with respect to Employers fiscal year in which the termination date occurs, equal to the greater of Employees Average Annual Performance Bonus (as defined in Section 5.4) or Employees bonus for the year immediately preceding Employees termination. Such additional bonus shall be payable to Employee within ninety (90) days of Employees termination date pursuant to Section 4.7.
5.12. Section 409A Compliance.
(a) General. It is the intention of both Employer and Employee that the benefits and rights to which Employee could be entitled in connection with termination of employment comply with Section 409A of the Code and the Treasury Regulations and other guidance promulgated or issued thereunder (Section 409A), and the provisions of this Agreement shall be construed in a manner consistent with that intention. If Employee or Employer believes, at any time, that any such benefit or right does not so comply, it shall promptly advise the other and shall negotiate reasonably and in good faith to amend the terms of such benefits and rights such that they comply with Section 409A of the Code (with the most limited possible economic effect on Employee and on Employer).
(b) Distributions on Account of Separation from Service. If and to the extent required to comply with Section 409A, no payment or benefit required to be paid under this Agreement on account of termination of Employees employment shall be made unless and until Employee incurs a separation from service, within the meaning of Section 409A.
(c) 6 Month Delay for Specified Employees.
(i) If Employee is a specified employee, then no payment or benefit that is payable on account of Employees separation from service, as that term is defined for purposes of Section 409A, shall be made before the date that is six months after Employees separation from service (or, if earlier, the date of Employees death) if and to the extent that such payment or benefit constitutes deferred compensation (or may be nonqualified deferred compensation) under Section 409A and such deferral is required to comply with the requirements of Section 409A. Any payment or benefit delayed by reason of the prior sentence shall be paid out or provided in a single lump sum at the end of such required delay period in order to catch up to the original payment schedule.
9
(ii) For purposes of this provision, Employee shall be considered to be a specified employee if, at the time of his or her separation from service, Employee is a key employee, within the meaning of Section 416(i) of the Code, of Employer (or any person or entity with whom Employer would be considered a single employer under Section 414(b) or Section 414(c) of the Code) any stock in which is publicly traded on an established securities market or otherwise.
(iii) Unless otherwise required to comply with Section 409A, a payment or benefit shall not be deferred pursuant to this provision if:
(x) it is not made on account of Employees separation from service, (y) it is required to be paid no later than within 2 1⁄2 months after the end of the taxable year of Employee in which the payment or benefit is no longer subject to a substantial risk of forfeiture, as that term is defined for purposes of Section 409A, or (z) the payment satisfies the following requirements: (A) it is being paid or provided due to Employers termination of Employees employment without Cause (Section 4.4) or Employees termination of employment after a Change in Control for the reasons set forth in Section 4.7 hereof, (B) it does not exceed two times the lesser of (1) Employees annualized compensation from Employer for the calendar year prior to the calendar year in which the termination of Employees employment occurs, and (2) the maximum amount of compensation that may be taken into account under a qualified plan pursuant to Section 401(a)(17) of the Code for the year in which Employees employment terminates, and (C) the payment is required under this Agreement to be paid no later than the last day of the second calendar year following the calendar year in which Employee incurs a separation from service.
(d) No Acceleration of Payments. Neither Employer nor Employee, individually or in combination, may accelerate any payment or benefit that is subject to Section 409A, except in compliance with Section 409A and the provisions of this Agreement, and no amount shall be paid prior to the earliest date on which it may be paid without violating Section 409A.
(e) Treatment of Each Installment as a Separate Payment. For purposes of applying the provisions of Section 409A to this Agreement, each separately identified amount to which Employee is entitled under this Agreement shall be treated as a separate payment. In addition, to the extent permissible under Section 409A, any series of installment payments under this Agreement shall be treated as a right to a series of separate payments.
10
(f) Reimbursements and In-Kind Benefits.
(i) Any reimbursements by Employer to Employee of any eligible expenses pursuant to Section 3.1 or 5.8 of this Agreement, that are not excludible from Employees income for Federal income tax purposes (Taxable Reimbursements) shall be made on or before the last day of the taxable year of Employee following the year in which the expense was incurred.
(ii) The amount of any Taxable Reimbursements, and the value of any in-kind benefits to be provided to Employee under this Agreement, during any taxable year of Employee shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year of Employee.
(iii) The right to Taxable Reimbursements, or in-kind benefits, shall not be subject to liquidation or exchange for another benefit.
5.13. Release. Employer shall provide Employee with a general release in the form attached as Exhibit C (subject to such modifications as Employer may reasonably request) within seven (7) days after Employees termination date. Payments or benefits to which Employee may be entitled pursuant to this Section 5 (other than any accrued but unpaid Base Salary and employee benefits as of the end of the Employment Period) (the Severance Amounts) shall be conditioned upon Employee executing the general release within 21 days after receiving it from Employer and the general release becoming irrevocable upon the expiration of 7 days following the Employees execution of it. Payment of the Severance Amounts shall be suspended during the period (the Suspension Period) that begins on Employees termination date and ends on the date (Suspension Termination Date) that is thirty-five (35) days after Employees termination date; provided, however, that this suspension shall not apply, and Employer shall be required to provide, any continued health insurance coverage that would be required under Section 5.9 hereof during the Suspension Period. If Employee executes the general release and the general release becomes irrevocable by no later than the Suspension Termination Date, then payment of any Severance Amounts that were suspended pursuant to this provision shall be made in the first payroll period that follows the Suspension Termination Date, and any Severance Amounts that are payable after the Suspension Termination Date shall be paid at the times provided in Section 5.
5.14. Vesting of Incentive Awards. Notwithstanding any contrary provision in this Agreement or any Equity Plan then maintained by MEDNAX, Inc., if , during the first twelve (12) months after a Change in Control, Employees employment is terminated pursuant to Section 4.4 or 4.7(a),(b)(d) or (e), then all of the Accelerated Awards will be fully vested and exercisable as of the effective date of such termination.
6. Successors; Binding Agreement.
6.1. Successors. Employer shall require any successor (whether direct or indirect, by purchase, merger, consolidation or otherwise) acquiring a majority of Employers voting common stock or any other successor to all or substantially all of the business and/or assets of Employer to expressly assume and agree to perform this Agreement in the same manner and to the same extent
11
that Employer would be required to perform it if no such succession had taken place and Employee hereby consents to any such assignment. In such event, Employer shall mean Employer as previously defined and any successor to its business and/or assets which executes and delivers the agreement provided for in this Section 6 or which otherwise becomes bound by all the terms and provisions of this Agreement by operation of law. This Section shall not limit Employees ability to terminate this Agreement in the circumstances described in Section 4.7 in the event of a Change in Control.
6.2. Benefit. This Agreement and all rights of Employee under this Agreement shall inure to the benefit of and be enforceable by Employees personal or legal representatives, executors, administrators, successors, heirs, distributees, devisees and legatees. If Employee should die after the termination date and amounts would have been payable to Employee under this Agreement if Employee had continued to live, including under Section 5 hereof, then such amounts shall be paid to Employees devisee, legatee, or other designee or, if there is no such designee, Employees estate.
7. Conflicts. This Agreement constitutes the entire agreement among the parties pertaining to the subject matter hereof and supersedes and revokes any and all prior or existing agreements, written or oral, relating to the subject matter hereof, and this Agreement shall be solely determinative of the subject matter hereof.
8. Restrictive Covenants; Confidential Information; Work Product; Injunctive Relief.
8.1. No Material Competition. Employer and Employee acknowledge and agree that a strong relationship and connection exists between Employer and its current and prospective patients, referral sources, and customers as well as the hospitals and healthcare facilities at which it provides professional services. Employer and Employee further acknowledge and agree that the restrictive covenants described in this Section are designed to enforce, and are ancillary to or part of, the promises contained in this Agreement and are reasonably necessary to protect the legitimate interests of Employer in the following: (1) the use and disclosure of the Confidential Information as described in Section 8.4; (2) the professional development activities described in Section 1.2; and (3) the goodwill of the Employer, as promoted by Employee as provided in Section 1.2. The foregoing listing is by way of example only and shall not be construed to be an exclusive or exhaustive list of such interests. Employee acknowledges that the restrictive covenants set forth below are of significant value to Employer and were a material inducement to Employer in agreeing to the terms of this Agreement. Employee further acknowledges that the goodwill and other proprietary interest of Employer will suffer irreparable and continuing damage in the event Employee enters into competition with Employer in violation of this Section.
Therefore, Employee agrees that, except with respect to services performed under this Agreement on behalf of Employer, Employee shall not, at any time during the Restricted Period (as defined below), for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer, participate or engage in or own an interest in, directly or indirectly, any individual proprietorship, partnership, corporation, joint venture, trust or other form of business entity, whether as an individual proprietor, partner, joint venturer, officer, director, member, employee, consultant,
12
independent contractor, stockholder, lender, landlord, finder, agent, broker, trustee, or in any manner whatsoever, if such entity or its affiliates is engaged in, directly or indirectly, Employers Business, as defined on Exhibit A hereto. Employee acknowledges that, as of the date hereof, Employees responsibilities will include matters affecting the businesses of Employer listed on Exhibit A. For purposes of this Section 8, the Restricted Period shall mean the Employment Period plus twenty-four (24) months in the event the Agreement is terminated for any other reason.
8.2. No Hire. Employee further agrees that Employee shall not, at any time during the Employment Period and for a period of twenty-four (24) months immediately following termination of this Agreement for any reason, for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer, intentionally, knowingly, or willingly employ, or intentionally, knowingly, or willingly permit any company or business directly or indirectly controlled by Employee to employ or otherwise engage (a) any person who is a then current employee or independent contractor of Employer or one of its affiliates, or (b) any person who was an employee or independent contractor of Employer or one of its affiliates in the prior six (6) month period, or in any manner seek to induce such persons to leave his or her employment or engagement with Employer or one of its affiliates (including without limitation for or on behalf of a subsequent employer of Employee).
8.3 Non-solicitation. Employee further agrees that Employee shall not, at any time during the Employment Period and for a period of twenty-four (24) months immediately following termination of this Agreement for any reason, for Employee or on behalf of any other person, persons, firm, partnership, corporation or employer, solicit or accept business from or take any action that would interfere with, diminish or impair the valuable relationships that Employer or its affiliates have with (i) hospitals or other health care facilities with which Employer or its affiliates have contracts to render professional services or otherwise have established relationships, (ii) patients, (iii) referral sources, (iv) vendors, (v) any other clients of Employer or its affiliates, or (vi) prospective hospitals, patients, referral sources, vendors or clients whose business Employee was aware that Employer or any affiliate of Employer was in the process of soliciting at the time of Employees termination (including potential acquisition targets).
8.4. Confidential Information. At all times during the term of this Agreement, Employer shall provide Employee with access to Confidential Information. As used in this Agreement, the term Confidential Information means any and all confidential, proprietary or trade secret information, whether disclosed, directly or indirectly, verbally, in writing or by any other means in tangible or intangible form, including that which is conceived or developed by Employee, applicable to or in any way related to: (i) patients with whom Employer has a physician/patient relationship; (ii) the present or future business of Employer; or (iii) the research and development of Employer. Without limiting the generality of the foregoing, Confidential Information includes: (a) the development and operation of Employers medical practices, including information relating to budgeting, staffing needs, marketing, research, hospital relationships, equipment capabilities, and other information concerning such facilities and operations and specifically including the procedures and business plans developed by Employer for use at the hospitals where Employer conducts its business; (b) contractual arrangements between the Employer and insurers or managed care associations or other payors; (c) the databases of Employer; (d) the clinical and research protocols of Employer, including coding guidelines; (e) the referral sources of Employer; (f) other confidential
13
information of Employer that is not generally known to the public that gives Employer the opportunity to obtain an advantage over competitors who do not know or use it, including the names, addresses, telephone numbers or special needs of any of its patients, its patient lists, its marketing methods and related data, lists or other written records used in Employers business, compensation paid to employees and other terms of employment, accounting ledgers and financial statements, contracts and licenses, business systems, business plan and projections, and computer programs. The parties agree that, as between them, this Confidential Information constitutes important, material, and confidential trade secrets that affect the successful conduct of Employers business and its goodwill. Employer acknowledges that the Confidential Information specifically enumerated above is special and unique information and is not information that would be considered a part of the general knowledge and skill Employee has or might otherwise obtain.
Notwithstanding the foregoing, Confidential Information shall not include any information that (i) was known by Employee from a third party source before disclosure by or on behalf of Employer, (ii) becomes available to Employee from a source other than Employer that is not, to Employees knowledge, bound by a duty of confidentiality to Employer, (iii) becomes generally available or known in the industry other than as a result of its disclosure by Employee, or (iv) has been independently developed by Employee and may be disclosed by Employee without breach of this Agreement, provided, in each case, that the Employee shall bear the burden of demonstrating that the information falls under one of the above-described exceptions.
Employee agrees that the terms of this Agreement shall be deemed Confidential Information for purposes of this Section. Employee shall keep the terms of this Agreement strictly confidential and will not, without the prior written consent of Employer, disclose the details of this Agreement to any third party in any manner whatsoever in whole or in part, with the exception of Employees representatives (such as tax advisors and attorneys) who need to know such information.
Employee agrees that Employee will not at any time, whether during or subsequent to the term of Employees employment with Employer, in any fashion, form or manner, unless specifically consented to in writing by Employer, either directly or indirectly, use or divulge, disclose, or communicate to any person, firm or corporation, in any manner whatsoever, any Confidential Information of any kind, nature, or description, subject to applicable law. The parties agree that any breach by Employee of any term of this Section is a material breach of this Agreement and shall constitute cause for the termination of Employees employment hereunder. In the event that Employee is ordered to disclose any Confidential Information, whether in a legal or a regulatory proceeding or otherwise, Employee shall provide Employer with prompt written notice of such request or order so that Employer may seek to prevent disclosure or, if that cannot be achieved, the entry of a protective order or other appropriate protective device or procedure in order to assure, to the extent practicable, compliance with the provisions of this Agreement. In the case of any disclosure required by law, Employee shall disclose only that portion of the Confidential Information that Employee is ordered to disclose in a legally binding subpoena, demand or similar order issued pursuant to a legal or regulatory proceeding.
All Confidential Information, and all equipment, notebooks, documents, memoranda, reports, files, samples, books, correspondence, lists, other written and graphic records, in any media (including electronic or video) containing Confidential Information or relating to the business of Employer, which Employee shall prepare, use, construct, observe, possess, or control shall be and remain Employers sole property (collectively Employer Property). Upon termination or expiration of this Agreement, or earlier upon Employers request, Employee shall promptly deliver to Employer all Employer Property, retaining none.
14
8.5. Ownership of Work Product. Employee agrees and acknowledges that (i) all copyrights, patents, trade secrets, trademarks, service marks, or other intellectual property or proprietary rights associated with any ideas, concepts, techniques, inventions, processes, or works of authorship developed or created by Employee during the course of performing work for Employer and any other work product conceived, created, designed, developed or contributed by Employee during the term of this Agreement that relates in any way to Employers Business (collectively, the Work Product), shall belong exclusively to Employer and shall, to the extent possible, be considered a work made for hire within the meaning of Title 17 of the United States Code. To the extent the Work Product may not be considered a work made for hire owned exclusively by Employer, Employee hereby assigns to Employer all right, title, and interest worldwide in and to such Work Product at the time of its creation, without any requirement of further consideration. Upon request of Employer, Employee shall take such further actions and execute such further documents as Employer may deem necessary or desirable to further the purposes of this Agreement, including without limitation separate assignments of all right, title, and interest in and to all rights of copyright and all right, title, and interest in and to any inventions or patents and any reissues or extensions which may be granted therefore, and in and to any improvements, additions to, or modifications thereto, which Employee may acquire by invention or otherwise, the same to be held and enjoyed by Employer for its own use and benefit, and for the use and benefit of Employers successors and assigns, as fully and as entirely as the same might be held by Employee had this assignment not been made.
8.6. Clearance Procedure for Proprietary Rights Not Claimed by Employer. In the event that Employee wishes to create or develop, other than on Employers time or using Employers resources, anything that may be considered Work Product but to which Employee believes Employee should be entitled to the personal benefit of, Employee agrees to follow the clearance procedure set forth in this Section. Before beginning any such work, Employee agrees to give Employer advance written notice and provide Employer with a sufficiently detailed written description of the work under consideration for Employer to make a determination regarding the work. Unless otherwise agreed in a writing signed by Employer prior to receipt, Employer shall have no obligation of confidentiality with respect to such request or description. Employer will determine in its sole discretion, within thirty (30) days after Employee has fully disclosed such plans to Employer, whether rights in such work will be claimed by Employer. If Employer determines that it does not claim rights in such work, Employer agrees to so notify Employee in writing and Employee may retain ownership of the work to the extent that such work has been expressly disclosed to Employer. If Employer fails to so notify Employee within such thirty (30) day period, then Employer shall be deemed to have agreed that such work is not considered Work Product for purposes of this Agreement. Employee agrees to submit for further review any significant improvement, modification, or adaptation that could reasonably be related to Employers Business so that it can be determined whether the improvement, modification, or adaptation relates to the business or interests of Employer. Clearance under this procedure does not relieve Employee of the restrictive covenants set forth in this Section 8.
15
8.7. Non-Disparagement. For a period of ten (10) years after the termination of this Agreement, Employee will not, directly or indirectly, as an individual or on behalf of a firm, corporation, partnership or other legal entity, make any disparaging or negative comment to any other person or entity regarding Employer or any of its affiliates, agents, attorneys, employees, officers and directors, Employees work conditions or circumstances surrounding Employees separation from Employer or otherwise impugn or criticize the name or reputation of Employer, its affiliates, agents, attorneys, employees, officers or directors, orally or in writing.
8.8. Review by Employee. Employee has carefully read and considered the terms and provisions of this Section 8, and having done so, agrees that the restrictions set forth in this Section 8 are fair and reasonably required for the protection of the interests of Employer. In the event that any term or provision set forth in this Section 8 shall be held to be invalid or unenforceable by a court of competent jurisdiction, the parties hereto agree that such invalid or unenforceable term(s) or provision(s) may be severed from this Agreement without, in any manner, affecting the remaining portions hereof. Without limiting other possible remedies available to Employer, Employee agrees that injunctive or other equitable relief will be available to enforce the covenants set forth in this Section, such relief to be without the necessity of posting a bond. In the event that, notwithstanding the foregoing, any part of the covenants set forth in this Section shall be held to be invalid, overbroad, or unenforceable by an arbitration panel or a court of competent jurisdiction, the parties hereto agree that such invalid, overbroad, or unenforceable provision(s) may be modified or severed from this Agreement without, in any manner, affecting the remaining portions of this Section 8 (all of which shall remain in full force and effect). In the event that any provision of this Section 8 related to time period or areas of restriction shall be declared by an arbitration panel or a court of competent jurisdiction to exceed the maximum time period, area or activities such arbitration panel or court deems reasonable and enforceable, said time period or areas of restriction shall be deemed modified to the minimum extent necessary to make the geographic or temporal restrictions or activities reasonable and enforceable.
8.9. Survival. The provisions of this Section 8 shall survive the termination of this Agreement and Employees employment with Employer. The provisions of this Section 8 shall apply during the time Employee is receiving Disability payments from Employer as a result of a termination of this Agreement pursuant to Section 4.2 hereof. In the event of a breach of this Section 8 by Employee, Employer retains the right to terminate any continuing payments to Employee provided for in Section 5 of this Agreement. The provisions of this Section 8 are expressly intended to benefit and be enforceable by other affiliated entities of Employer, who are express third party beneficiaries hereof. Employee shall not assist others in engaging in any of the activities described in the foregoing restrictive covenants.
9. Arbitration. Any controversy or claim arising out of or relating to this Agreement, or any alleged breach hereof shall be finally determined by a single arbitrator, jointly selected by the Employee and Employer, provided that if Employee and Employer are unable to agree upon a single arbitrator after reasonable efforts, the arbitrator shall be an impartial arbitrator selected by the American Arbitration Association. Each party hereto shall share equally the costs of the arbitrator, and the parties agree that the costs of arbitration shall not be subject to reapportionment by the arbitrator. The arbitration proceedings shall be held in Sunrise, Florida, unless otherwise mutually
16
agreed by the parties, and shall be conducted in accordance with the American Arbitration Association National Rules for the Resolution of Employment Disputes then in effect. Judgment on the award rendered by the arbitration panel may be entered and enforced by any court having jurisdiction thereof. Any such arbitration shall be treated as confidential by all parties thereto, except as otherwise provided by law or as otherwise necessary to enforce any judgment or order issued by the arbitrators.
Notwithstanding anything herein to the contrary, if Employer or Employee shall require immediate injunctive relief, then the party shall be entitled to seek such relief in any court having jurisdiction, and if the party elects to do so, the other party hereby consents to the jurisdiction of the state and federal courts sitting in the State of Florida and to the applicable service of process. Employee and Employer hereby waive and agree not to assert, to the fullest extent permitted by applicable law, any claim that (i) they are not subject to the jurisdiction of such courts, (ii) they are immune from any legal process issued by such courts and (iii) any litigation or other proceeding commenced in such courts is brought in an inconvenient forum. In the event that either party hereto brings suit seeking injunctive relief, the party found to be at fault shall pay all reasonable court costs and attorneys fees of the other, whether such costs and fees are incurred in a court of original jurisdiction or one or more courts of appellate jurisdiction.
10. Governing Law. This Agreement shall be governed by and construed in accordance with the laws of the State of Florida without regard to its conflict of laws principles to the extent that such principles would require the application of laws other than the laws of the State of Florida.
11. Notices. Any notice required or permitted to be given under this Agreement shall be in writing and shall be deemed to have been given when delivered by hand or when deposited in the United States mail by registered or certified mail, return receipt requested, postage prepaid, addressed as follows:
If to Employer: |
If to Employee: | |
Mednax Services, Inc. |
John C. Pepia | |
1301 Concord Terrace |
c/o MEDNAX Services, Inc. | |
Sunrise, FL 33323 |
1301 Concord Terrace | |
Attention: General Counsel |
Sunrise, FL 33323 |
or to such other addresses as either party hereto may from time to time give notice of to the other in the aforesaid manner.
12. Benefits: Binding Effect. This Agreement shall be for the benefit of and binding upon the parties hereto and their respective heirs, personal representatives, legal representatives, successors and, where applicable, assigns. Notwithstanding the foregoing, Employee may not assign the rights or benefits hereunder without the prior written consent of Employer.
13. Severability. The invalidity of any one or more of the words, phrases, sentences, clauses or sections contained in this Agreement shall not affect the enforceability of the remaining portions of this Agreement or any part thereof, all of which are inserted conditionally on their being valid in law, and, in the event that any one or more of the words, phrases, sentences, clauses or sections contained in this Agreement shall be declared invalid, this Agreement shall be construed as if such invalid word or words, phrase or phrases, sentence or sentences, clause or clauses, or section or sections had not been inserted. If such invalidity is caused by length of time or size of area, or both, the otherwise invalid provision will be considered to be reduced to a period or area, which would cure such invalidity.
17
14. Waivers. The waiver by either party hereto of a breach or violation of any term or provision of this Agreement shall not operate nor be construed as a waiver of any subsequent breach or violation.
15. Damages. Nothing contained herein shall be construed to prevent Employer or Employee from seeking and recovering from the other damages sustained by either or both of them as a result of a breach of any term or provision of this Agreement.
16. No Third Party Beneficiary. Except as provided in Section 8.9, nothing expressed or implied in this Agreement is intended, or shall be construed, to confer upon or give any person (other than the parties hereto and, in the case of Employee, Employees heirs, personal representative(s) and/or legal representative) any rights or remedies under or by reason of this Agreement. No agreements or representations, oral or otherwise, express or implied, have been made by either party with respect to the subject matter of this Agreement which agreements or representations are not set forth expressly in this Agreement, and this Agreement supersedes any other employment agreement between Employer and Employee.
17. Assignment. This Agreement may be assigned by Employer upon notice to Employee.
18
IN WITNESS WHEREOF, the undersigned have executed this Agreement this 1st day of August, 2019, effective as of the Effective Date.
EMPLOYER: | EMPLOYEE: | |||||||
MEDNAX SERVICES, INC. | ||||||||
By: | /s/ Stephen D. Farber | By: | /s/ John C. Pepia | |||||
Stephen D. Farber | John C. Pepia | |||||||
Executive Vice President and | ||||||||
Chief Financial Officer |
19
EXHIBIT A
BUSINESS OF EMPLOYER
As of the date hereof, Employer, directly or through its affiliates, provides professional medical services and all aspects of practice management services in medical practice areas that include, but are not limited to, the following (collectively referred to herein as Employers Business):
(1) Neonatology, including hospital well baby care;
(2) Maternal-Fetal Medicine, including general obstetrics services;
(3) Pediatric Cardiology;
(4) Pediatric Intensive Care, including Pediatric Hospitalist Care;
(5) Newborn hearing screening services;
(6) Pediatric Surgery;
(7) Pediatric Emergency Medicine;
(8) Anesthesiology, critical care medicine and pain management; and
(9) Radiology and Teleradiology.
References to Employers Business in this Agreement shall include such other medical service lines, practice management services and other businesses in which Employer is engaged during the Employment Period; provided, that to be considered a part of Employers Business, Employer must have engaged in such other service line, practice management service or other business at least six (6) months prior to the termination date of this Agreement. For purposes of this Exhibit A, businesses of Employer shall include the businesses conducted by Employers subsidiaries, entities under common control and affiliates as defined under Rule 144 of the Securities Act of 1933, as amended. Such affiliates shall include the professional corporations and associations whose operating results are consolidated with Employer for financial reporting purposes.
Notwithstanding the foregoing, Employer acknowledges and agrees to the following exceptions and clarifications regarding the scope of Employers Business.
A. Hospital Services. Employer and Employee acknowledge that, as of the date hereof, Employer does not currently operate hospitals, hospital systems or universities. Nevertheless, the businesses of hospitals, hospital systems and universities would be the same as Employers Business where such hospitals, hospital systems or universities provide or contract with others to provide some or all of the medical services included in Employers Business. Therefore, the parties desire to clarify their intent with respect to the limitations on Employees ability to work for or contract with others to provide services for a hospital, hospital system or university during the Employment Period and during the Restricted Period. Section 8.1 shall not be deemed to restrict Employees ability to work for a hospital, hospital system or university if the hospital, hospital system or university does not provide any of the medical services included in Employers Business. Furthermore, even if a hospital, hospital system or university provides medical services that are included in Employers
20
Business, Employee may work for such hospital, hospital system or university if Employee has no direct supervisory responsibility for or involvement in the hospitals, hospital systems or universitys medical services that are Employers Business. Finally, Employer agrees that Employee may hold direct supervisory responsibility for or be involved in the medical services of a hospital, hospital system or university that are included in Employers Business so long as such hospital, hospital system or university is located at least ten (10) miles from a medical practice owned or operated by Employer or its affiliate. Subject to paragraph B below, the provisions of this paragraph shall not apply to the extent that, after the date hereof, Employer enters into the business of operating a hospital or hospital system.
B. De Minimus Exception. Employer agrees that a medical service line (other than those listed in items 1 through 9 above), practice management service or other business in which Employer is engaged shall not be considered to be a part of Employers Business if such medical service line, practice management service or other business constitutes less than three percent (3%) of Employers annual revenues.
C. Certain Ownership Interests. It shall not be deemed to be a violation of Section 8.1 for Employee to: (i) own, directly or indirectly, one percent (1%) or less of a publicly-traded entity that has a market capitalization of $1 billion or more; (ii) own, directly or indirectly, five percent (5%) or less of a publicly-traded entity that has a market capitalization of less than $1 billion; or (iii) own, directly or indirectly, less than ten percent (10%) of a privately-held business or company, if Employee is at all times a passive investor with no board representation, management authority or other special rights to control operations of such business or company.
21
EXHIBIT B
COMPENSATION
Performance Bonus: Up to 50% of Employees Base Salary.
Equity Compensation: Employee shall be eligible for equity compensation as approved by the Compensation Committee of the Board of Directors of MEDNAX, Inc.
22
EXHIBIT C
FORM OF RELEASE
GENERAL RELEASE OF CLAIMS
1. _______________ (Employee), for himself and his family, heirs, executors, administrators, legal representatives and their respective successors and assigns, in exchange for the consideration received pursuant to Section 5.[ ] of the Employment Agreement to which this release is attached as Exhibit C (the Employment Agreement), does hereby release and forever discharge _____________________ (Employer), its subsidiaries, affiliated companies, successors and assigns, and its current or former directors, officers, employees, shareholders or agents in such capacities (collectively with Employer, the Released Parties) from any and all actions, causes of action, suits, controversies, claims and demands whatsoever, for or by reason of any matter, cause or thing whatsoever, whether known or unknown including, but not limited to, all claims under any applicable laws arising under or in connection with Employees employment or termination thereof, whether for discrimination, harassment, retaliation, tort, breach of express or implied employment contract, wrongful discharge, intentional infliction of emotional distress, or defamation or injuries incurred on the job or incurred as a result of loss of employment. Employee acknowledges that Employer encouraged him to consult with an attorney of his choosing, and through this General Release of Claims encourages Employee to consult with his attorney with respect to possible claims under the Age Discrimination in Employment Act (ADEA) and that he understands that the ADEA is a Federal statute that, among other things, prohibits discrimination on the basis of age in employment and employee benefits and benefit plans. Without limiting the generality of the release provided above, Employee expressly waives any and all claims under ADEA that he may have as of the date hereof. Employee further understands that by signing this General Release of Claims he is in fact waiving, releasing and forever giving up any claim under the ADEA as well as all other laws within the scope of this paragraph 1 that may have existed on or prior to the date hereof. Notwithstanding anything in this paragraph 1 to the contrary, this General Release of Claims shall not apply to (i) any actions to enforce rights to receive any payments or benefits which may be due Employee pursuant to Section 5.[ ] of the Employment Agreement, or under any of Employers employee benefit plans, (ii) any rights or claims that may arise as a result of events occurring after the date this General Release of Claims is executed, (iii) any indemnification rights Employee may have as a former officer or director of Employer or its subsidiaries or affiliated companies, (iv) any claims for benefits under any directors and officers liability policy maintained by Employer or its subsidiaries or affiliated companies in accordance with the terms of such policy, and (v) any rights as a holder of equity securities of Employer.
2. Employee represents that he has not filed against the Released Parties any complaints, charges, or lawsuits arising out of his employment, or any other matter arising on or prior to the date of this General Release of Claims, and covenants and agrees that he will never individually or with any person file, or commence the filing of, any charges, lawsuits, complaints or proceedings with any governmental agency, or against the Released Parties with respect to any of the matters released by Employee pursuant to paragraph 1 hereof (a Proceeding).
23
3. Notwithstanding anything in this Agreement to the contrary, nothing in this Agreement or any other agreement between Employer and Employee shall prevent Employee from filing a charge, sharing information and communicating in good faith, without prior notice to the Company, with any federal government agency having jurisdiction over the Company or its operations, and cooperating in any investigation by any such federal government agency; However, to the maximum extent permitted by law, Employee agrees that if such an administrative claim is made, Employee shall not be entitled to recover any individual monetary relief or other individual remedies.
4. Employee hereby acknowledges that Employer has informed him that he has up to twenty-one (21) days to sign this General Release of Claims and he may knowingly and voluntarily waive that twenty-one (21) day period by signing this General Release of Claims earlier. Employee also understands that he shall have seven (7) days following the date on which he signs this General Release of Claims within which to revoke it by providing a written notice of his revocation to Employer.
5. Employee acknowledges that this General Release of Claims will be governed by and construed and enforced in accordance with the internal laws of the State of Florida applicable to contracts made and to be performed entirely within such State.
6. Employee acknowledges that he has read this General Release of Claims, that he has been advised that he should consult with an attorney before he executes this general release of claims, and that he understands all of its terms and executes it voluntarily and with full knowledge of its significance and the consequences thereof.
7. This General Release of Claims shall take effect on the eighth day following Employees execution of this General Release of Claims unless Employees written revocation is delivered to Employer within seven (7) days after such execution.
_______________, 20__ |
24
Exhibit 21.1
Subsidiaries
Name of Subsidiary | State of Incorporation |
Line of Business |
Number of Omitted Subsidiaries Operating |
|||||||||||||
in the United States |
in Foreign Countries |
|||||||||||||||
Mednax Services, Inc. |
Florida | Physician Services | 13 | 0 | ||||||||||||
Pediatrix Medical Group, Inc. |
Florida | Physician Services | 10 | 0 | ||||||||||||
American Anesthesiology, Inc. |
Florida | Physician Services | 9 | 0 |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the incorporation by reference in the Registration Statements on Form S-8 (Nos. 333-181667, 333-153397, 333-151272, 333-101225, 333-208698, and 333-231826) of MEDNAX, Inc. of our report dated February 20, 2020 relating to the financial statements and financial statement schedule and the effectiveness of internal control over financial reporting, which appears in this Form 10-K.
/s/ PricewaterhouseCoopers LLP
Miami, Florida
February 20, 2020
Exhibit 31.1
CERTIFICATIONS
I, Roger J. Medel, M.D., certify that:
1. | I have reviewed this annual report on Form 10-K of MEDNAX, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. | The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Date: February 20, 2020
By: | /s/ Roger J. Medel, M.D. | |
Roger J. Medel, M.D. | ||
Chief Executive Officer | ||
(Principal Executive Officer) |
Exhibit 31.2
CERTIFICATIONS
I, Stephen D. Farber, certify that:
1. | I have reviewed this annual report on Form 10-K of MEDNAX, Inc.; |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrants other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
(a) | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
(b) | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
(c) | Evaluated the effectiveness of the registrants disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
(d) | Disclosed in this report any change in the registrants internal control over financial reporting that occurred during the registrants most recent fiscal quarter (the registrants fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrants internal control over financial reporting; and |
5. | The registrants other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrants auditors and the audit committee of the registrants board of directors (or persons performing the equivalent functions): |
(a) | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrants ability to record, process, summarize and report financial information; and |
(b) | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrants internal control over financial reporting. |
Date: February 20, 2020
By: | /s/ Stephen D. Farber | |
Stephen D. Farber | ||
Executive Vice President and Chief Financial Officer (Principal Financial Officer) |
Exhibit 32
Certification Pursuant to 18 U.S.C Section 1350
(Adopted by Section 906 of the Sarbanes-Oxley Act of 2002)
In connection with the Annual Report of MEDNAX, Inc. on Form 10-K for the year ended December 31, 2019 (the Report), each of the undersigned hereby certifies, pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that (i) the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and (ii) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of MEDNAX, Inc.
A signed original of this written statement required by Section 906 has been provided to MEDNAX, Inc. and will be retained by MEDNAX, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.
February 20, 2020
By: | /s/ Roger J. Medel, M.D. | |
Roger J. Medel, M.D. | ||
Chief Executive Officer (Principal Executive Officer) |
By: | /s/ Stephen D. Farber | |
Stephen D. Farber | ||
Executive Vice President and (Principal Financial Officer) |